Next Article in Journal
Oak Species Quercus robur L. and Quercus petraea Liebl. Identification Based on UHPLC-HRMS/MS Molecular Networks
Previous Article in Journal
Gallstone Formation Follows a Different Trajectory in Bariatric Patients Compared to Nonbariatric Patients
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Metabolites
Volume 11
Issue 10
10.3390/metabo11100683
metabolites-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Fungal Depsides—Naturally Inspiring Molecules: Biosynthesis, Structural Characterization, and Biological Activities

by
Sabrin R. M. Ibrahim
1,2,*,
Alaa Sirwi
3,
Basma G. Eid
4,
Shaimaa G. A. Mohamed
5 and
Gamal A. Mohamed
3,6
1
Preparatory Year Program, Batterjee Medical College, Jeddah 21442, Saudi Arabia
2
Department of Pharmacognosy, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt
3
Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia
4
Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia
5
Faculty of Dentistry, British University, Suez Desert Road, El Sherouk City 11837, Egypt
6
Department of Pharmacognosy, Faculty of Pharmacy, Al-Azhar University, Assiut Branch, Assiut 71524, Egypt
*
Author to whom correspondence should be addressed.
Metabolites 2021, 11(10), 683; https://doi.org/10.3390/metabo11100683
Submission received: 16 July 2021 / Revised: 5 September 2021 / Accepted: 2 October 2021 / Published: 5 October 2021
(This article belongs to the Section Microbiology and Ecological Metabolomics)
Browse Figures
Versions Notes

Abstract

:
Fungi represent a huge reservoir of structurally diverse bio-metabolites. Although there has been a marked increase in the number of isolated fungal metabolites over the past years, many hidden metabolites still need to be discovered. Depsides are a group of polyketides consisting of two or more ester-linked hydroxybenzoic acid moieties. They possess valuable bioactive properties, such as anticancer, antidiabetic, antibacterial, antiviral, anti-inflammatory, antifungal, antifouling, and antioxidant qualities, as well as various human enzyme-inhibitory activities. This review provides an overview of the reported data on fungal depsides, including their sources, biosynthesis, physical and spectral data, and bioactivities in the period from 1975 to 2020. Overall, 110 metabolites and more than 122 references are confirmed. This is the first review of these multi-faceted metabolites from fungi.

1. Introduction

Fungi are widespread cosmopolitan organisms that represent the second-largest class of organisms after insects [1]. For decades, they have been seen as harmful, causing health hazards and spoiling foods. Today, the view on fungi has altered to take into account their advantageous effects, which have become apparent in biotechnological and industrial fields, as well as the production of structurally unique and life-saving metabolites [2,3,4,5]. In the past decades, the number of bioactive metabolites isolated from fungi has been rapidly increased due to their wide diversity of ecological and environmental niches across the globe, including marine, terrestrial, and water environments where they function as pathogens, symbionts, and saprobes [6,7]. Fungi-derived metabolites have made remarkable contributions to the process of drug discovery [8,9,10,11,12,13,14,15,16]. They have been used as antibiotics, herbicides, pesticides, anti-infectives, immuno-suppressants, and anticancer agents [6,7,17]. Depsides are simple polyketides that are formed by the condensation of two or more hydroxybenzoic acid moieties via ester linkage; the COOH group of one molecule is esterified with a phenolic OH group of the second molecule. They could be β-orcinol (β-orsellinic acid) or orcinol (orsellinic acid) derivatives, relying on the existence of the C3 methyl group on both rings (Figure 1). The ring with an ester-carbonyl is referred to as ring A and the other as ring B. Their major structural variations are the attached alkyl chains’ length, the degree of chain oxidation, and the degree of methylation of OH and COOH groups [18]. The OH groups usually exist at the aromatic carbons, C-3′/C-4′/C-2 or C-4, and other oxygenated substituents are usually connected to the skeleton, such as carboxyl and methoxyl substituents [19].
Depsides are common lichen metabolites [20,21,22]. However, they have also been reported in some higher plants and fungi [19,23,24,25,26,27]. Contrary to the lichen depsides, fungal depsides are not widely distributed and are isolated only from a restricted number of fungi (Table 1). It was reported that depsides possess remarkable bioactivities: anticancer, anti-diabetic, antibacterial, antiviral, anti-inflammatory, antifungal, antifouling, antioxidant, and various enzyme inhibitory activities. Therefore, these metabolites are of considerable importance as a prospective lead motif for medicinal chemistry. Our review of the literature indicated that there is currently no review on fungal depsides. Herein, 110 depsides reported in the literature from fungal sources have been listed, with a summary of their biosynthesis, physical constants, spectral data, sources, bioactivities, and references (Table 1, Table 2 and Table S1, Figure 2, Figure 3, Figure 4, Figure 5, Figure 6, Figure 7, Figure 8, Figure 9, Figure 10, Figure 11, Figure 12, Figure 13, Figure 14, Figure 15, Figure 16 and Figure 17). The data was displayed for each compound in the following manner: name, chemical structure, optical rotation, melting point, UV, molecular and weight formulae, NMR, and reference(s) (Table S1). The principal goal of this work is to provide the researchers with detailed references that can assist them in the rapid identification of isolated depsides by comparing their physical and spectral data. Nevertheless, highlighting the bioactivities of these metabolites may attract the attention of synthetic and medicinal chemists to synthesize new agents, using known depsides as start materials. Literature searches for published studies were performed through diverse databases: Web of Science, PubMed (MedLine), GoogleScholar, Scopus, SciFinder, Springer-Link, Wiley, and ACS (American Chemical Society) Publications using keywords (depsides, isolation, fungi, biosynthesis, NMR, and biological activities).

2. Biosynthesis of Depsides

Depsides are acetyl-poly-malonyl-derived polyketides that are biosynthesized by polyketide synthase (PKS) [28,29,30,31,32,33,34]. PKS is composed of a minimal set of KS (ketosynthase), AT (acyltransferase), and ACP (acyl carrier protein) domains [30]. The non-reduced framework of the depside rings reveals that its corresponding PKS belongs to non-reducing PKSs (NR-PKSs). Depsides consist of two orsellinic acid molecules, connected by an ester linkage. Therefore, orsellinic acid can be considered the constructing unit of all depsides [28]. Biosynthetically, orsellinic acid is produced from a linear tetraketide chain. This chain is formed through an acetate-malonate pathway that is catalyzed by PKSs [29,30]. The tetraketide chain forming β-orsellinic acid (methyl-3-orsellinate) is produced by introducing a CH3 group obtained from SAM (S-adenosylmethionine) by the methyl transferase (CMeT) domain of the corresponding PKS [31]. Then, the non-enzymatic 2,7-aldol condensation of these chains produces orsellinic and β-orsellinic acids. Furthermore, the molecular skeleton is probably designed by post-biosynthetic tailoring enzymes, such as cyclases and hydrolases [18]. p-Depsides are produced by the condensation of either orsellinic acid and orcinol derivatives or by two methyl-3-orsellinate or orsellinate moieties, through the formation of an ester [12]. The consequent condensation of an additional unit produces a tri-depside, and two moieties yield a tetra-depside [32]. Moreover, depsides containing alkyl side-chains can be produced by the reduction of the terminal ketone groups, resulting in the required saturated alkyl moieties. m-Depsides are formed through the hydroxylation of the para-depside B-ring, subsequently followed by rearrangement [33] (Figure 2).

3. Biological Activities

Despite the unique structures of depsides, they have not been well investigated in terms of their pharmacological activities. The literature survey revealed that depsides have various biological activities (Table 2). Thus, an overview of their reported pharmacological activities is summarized in Table 2 and is described in detail below.

3.1. Antitumor Activity

Cancer is considered the second cause of death after cardiovascular diseases [34]. In 2020, around 10 million deaths were estimated to have been due to cancer, 70% of which were in middle- and low-income countries [35]. Most of the anticancer agents cannot distinguish between abnormal and normal cells; thus, researchers have been directed to develop selective and safe anticancer drugs that target the abnormal cancerous cells and have minimal effects on normal cells. Fungi represent an important source of anticancer agents, with significant benefits against various tumors [36]. It is noteworthy to mention that most of the reported depsides showed activity on cancer cells with no or little effect on normal cells.
Lünne et al. [37] evaluated the antitumor effect of lecanoric acid (1) and ethyl lecanorate (2) purified from Claviceps purpurea on HepG2 (human liver cancer cells) and CCF-STTG1 (human astrocytoma cells) using the CTC (5-cyano-2,3-bis(4-methylphenyl)-2H-tetrazolium chloride) assay. Both metabolites produced a dose-dependent antitumor effect on the tested cell lines. They reduced the CCF-STTG1 cell viability down to ~60%, at a concentration of 40 μM, and HepG2 cell viability by ~30% and 40%, respectively. Similar to HepG2 cells, 2 had the strongest antitumor effect on CCF cells (IC50 value of 54 μM) [37]. In the MTT ((3-(4,5-dimethylthiazol-2-yl))-2,5-diphenyl-2H-tetrazolium bromide) assay, aspergisides A (3), B (4), and C (5) showed weak antitumor activity, with IC50 values in the range of 45–114 µM toward Vero, MCF-7, and KB cell lines, compared with doxorubicin [38]. MS-3 (22) was inactive against Ehrlich ascites for leukemia and carcinoma in vivo; however, it was active toward Yoshida sarcoma cells (ID5o value of 85 µg/mL) in vitro. Its activity was suggested to be due to a glyoxalase inhibition, as it possessed a glyoxalase inhibitory effect with an ID50 value of 12 µg/mL in the spectrophotometric assay [39]. In addition, 23 possessed significant antitumor activity toward A549 and HepG2, with IC50 values of 13.14 and 49.02 µM, respectively, compared to cisplatin (IC50 14.33 and 18.74, respectively) in the MTT assay [40]. Compounds 27–29 were assayed against NCI-H187, Vero, BC, and KB cells, employing an MTT assay. Compounds 27 and 28 exhibited a significant antitumor effect against BC, with IC50 values of 8.8 and 4.4 µM, respectively, compared to ellipticine (IC50 0.49 µM), while they showed weak to moderate effectiveness toward other cell lines, with IC50 values ranging from 13.0 to 34.3 µM [41]. Arenicolins A (30) and B (31), two new depsides having C-glycosyl moiety and dual heptyl side-chains, were isolated from Penicillium arenicola and assessed for antitumor activity at a concentration of 30.0 μM toward IMR-32, HCT-116, and BT-474 cell lines using an ICC (immunocytochemistry) assay. Compound 30 reduced cell viability with IC50 values of 6.0, 7.3, and 9.7 μM, respectively, compared to 5-FU (5-fluorouracil, IC50 6.5 μM for HCT-116 and 5.7 μM for IMR-32). However, 31 did not have a significant antitumor effect toward the tested cell lines at a concentration of > 30 μM [42].
CRM646-A (36) and CRM646-B (37) were discovered from Acremonium sp. that showed a potent anti-metastatic capacity toward B16-F10 melanoma cells, with an IC50 value of 15 µM for 36 and IC50 30 µM for 37 [43]. They also caused the dose-dependent inhibition of heparinase, with IC50 values of 3 and 10 µM, respectively, in comparison to suramin (IC50 value of 5 µM) [43,44]. Asami et al. established that CRM646-A (36) induced the inhibition of cells’ invasion, migration, and growth in tumor cells, due to its induction of nucleus condensation, plasma membrane disruption, and morphological changes in result to the increase in Ca2+ levels; thus, it could potentially be used as an effective anti-metastatic agent [45]. Compounds 45 and 46 in the MTT assay showed an antitumor effect against A549 and MAD-MB-435, with IC50 values of 16.82 and 37.01 μM, and 20.75 and 37.73 μM, respectively, compared with epirubicin (IC50 0.26 and 5.60 μM, respectively); however, 11 did not exhibit obvious activity [46]. Togashi et al. reported that 36 and 49 prohibited telomerase activity at doses of 3.2 and 32 µM, respectively. In addition, they inhibited viral reverse transcriptase activity at almost the same dose levels; therefore, they may inhibit universal RNA-dependent DNA polymerases [47]. Compound 50, a tridepside, was obtained from MSX 55526 fungus and showed moderate activity against the MCF-7, H460, and SF268 cell lines in the SRB assay, with IC50 values of 7.3, 6.6, and 8.1 µM, respectively, compared to camptothecin (IC50 0.07, < 0.01, and 0.04 µM, respectively) [48].

3.2. Antimicrobial Activity

The wide use of antibiotics leads to the development of resistant microbes [85]. Moreover, the number of efficient drugs against life-threatening fungal and bacterial infections has decreased dramatically because of emerging pathogens that are multidrug-resistant (MDR), which is the biggest obstacle to success during the treatment of infectious diseases [86]. Therefore, there is a growing demand for new antimicrobial compounds. Fungi are considered an important source of novel antimicrobials because of their rich secondary metabolites and abundant species diversity. Bacterial enoyl-ACP (acyl carrier protein) reductase accelerates the last and rate-limiting step in type II FAS (bacterial fatty acid synthesis) [87,88]. Enoyl-ACP reductase includes three isoforms, FabK, FabI, and FabL. It is found in most bacteria: S. aureus (FabI), Streptococcus pneumonia (FabK), P. aeruginosa and Enterococcus faecalis (FabK and FabI), B. subtilis (FabI and FabL), and Mycobacterium tuberculosis (InhA, a FabI homolog) [61,89]. This enzyme has been established as a novel target for treatment against infections produced by MDR pathogens.
Phainuphong et al. purified three new depsides, aspergisides A–C (3–5) from Aspergillus unguis, and assessed their antimicrobial potential against MRSA (methicillin-resistant S. aureus), S. aureus, C. albicans, flucytosine-resistant C. neoformans, and M. gypseum [38]. Compound 3 had a weak antibacterial activity toward S. aureus and MRSA, with an MIC (minimal inhibitory concentrations) value of 8 µg/mL, while 4 and 5 were inactive, with MIC values of 32–200 µg/mL in the agar diffusion method [38]. Setophoma sp. associated with guava fruits produced compounds 6–8 and 66–69 [19]. They did not have growth inhibition activity toward E. coli. However, 66–69 demonstrated inhibition of S. aureus with MIC values of 100, 6.25, 50, and 25 µg/mL, respectively, in comparison to tetracycline (MIC 3.12 µg/mL) [19]. Compounds 6 and 7 were inactive. Moreover, all compounds did not exhibit quorum-sensing inhibitory activity. Studying the structural activity relationship revealed that the activity increased with the full methylation of the B-ring; however, the additional CH3 group at ring A, especially at C-2, resulted in a decrease in activity [19]. The agonodepsides A (12) and B (13) were isolated from the filamentous fungus, F7524 [50]. In the fluorometric InhA assay, 12 inhibited M. tuberculosis InhA with an IC50 value of 75 µM, while 13 was inactive at 100 µM, compared with triclosan (IC50 3.0 µM) [50].
Emericella unguis yielded 14, which had antibacterial activity against S. aureus, and was inactive against Vibrio parahaemolyticus in the agar diffusion assay [51]. Stereum rameale afforded 22, which was found to show powerful antibacterial activity toward B. subtilis, B. cereus, and S. aureus, with IZDs (inhibition zone diameters) of 25, 25 and 28 mm, respectively, while it showed no antibacterial activity against E. coli, Salmonella sp., and P. aeruginosa. Its MBCs (minimal bactericidal concentrations) were 10, 50, and 100 μg/mL for B. subtilis, B. cereus, and S. aureus, respectively [57]. Compounds 23 and 24 showed inhibitory activity against both S. aureus and MRSA with MIC values of 25.0 µg/mL, and antibacterial potential toward B. subtilis (MICs 25.0 and 50.0 µg/mL, respectively), in comparison to vancomycin (MICs 1.0, 1.0, and 0.5 µg/mL, respectively) in the agar plate diffusion assay. They had a weak antibacterial potential against P. aeruginosa [40]. The new depsides, arenicolins A (30) and B (31) that were purified from Penicillium Arenicola, did not show any growth inhibition toward S. aureus, C. albicans, and C. neoformans at a concentration of 100 μg/mL, utilizing the agar diffusion assay [42]. Kwon et al. reported that the depside galactopyranoside derivative 32, isolated from Sporothrix sp., strongly inhibited S. pneumoniae FabK and S. aureus FabI, with IC50 values of 9.2 and 3.2 µM, respectively [61]. It also exhibited antibacterial activity against MRSA CCARM 3506 and CCARM 3167, as well as S. aureus RN4220, with MIC values of 16–32 µg/mL and strong activity against B. subtilis (KCTC 1021) and E. faecalis (KCTC 5191), with MIC values of 8–16 µg/mL [61]. Another study by Kwon et al. revealed that 32 prohibited M. tuberculosis InhA with IC50 value of 9.6 µM [89]. Moreover, 32 (conc. of 128) had a weak anti-bacterial capacity against M. tuberculosis, with a growth inhibition of 17.9% in the microbroth dilution [89]. Sporothrix sp. yielded 34 and 35. Compound 34 exhibited weak antimicrobial activity against S. aureus, E. faecium, and B. subtilis (MIC values of 12.5, 100, and 12.5 µg/mL, respectively) and showed no activity against C. albicans, P. aeruginosa, E. coli, P. vulgaris, S. sonnei, S. typhi, and K. pneumoniae at a concentration of 100 µg/mL. However, 35 had weak activity against S. aureus and B. subtilis and no activity against the others [63]. In 2017, Aqueveque et al. isolated 41 from Stereum hirsutum, which showed an antifungal capacity against Botrytis cinerea, one of the most harmful phytopathogenic fungi, causing the crop disease known as grey mold [58]. It showed a significant inhibition of B. cinerea mycelial growth at concentrations of 1000 and 2000 µg/mL, reaching 67% and 76%, respectively. At a concentration of 500 µg/mL, it produced 96% inhibition of sporulation. It showed an MIC of 10 µg/mL and MFC (minimal fungicidal concentration) of 50 µg/mL, compared with rovral (MFC of 10 µg/mL and MIC of 1 µg/mL) in the microdilution plate assay [58].
Compound 45, a new tridepside produced by Colletotrichum gloeosporioides and associated with Artemisia mongolica, was tested in the disk diffusion assay for B. subtilis, S. aureus, S. lutea, Pseudomonas sp., C. albicans, A. niger, C. elegans, H. sativum, and T. rubrum. It exhibited antibacterial potential toward B. subtilis (MIC 25 µg/mL), S. aureus (MIC 50 µg/mL), and S. lutea (MIC 50 µg/mL) in comparison to ampicillin (MIC values of 0.05, 0.5, and 0.01 µg/mL, respectively) and an antifungal effect toward H. sativum, with an MIC value of 50 µg/mL, relative to triadimefon (MIC value of 20 µg/mL) [65].
Phoma sp. associated with Kandelia candel yielded the compounds 11, 45, and 46. Compound 45 showed marked antimicrobial activity against B. subtilis, P. aeruginosa, MRSA, and C. albicans, with MIC values ranging from 3.27 to 6.55 μg/mL, compared with ampicillin (MIC values of 0.07, 0.15, and 0.15, respectively) and ketoconazole (MIC 0.10 μg/mL) in the disk diffusion assay. Moreover, it had weak activity toward Salmonella typhimurium with an MIC value of 26.20 μg/mL. Compound 46 was active against MRSA and P. aeruginosa, with MIC values of 3.36 and 1.67 μg/mL, respectively, and was weakly active toward B. subtilis (26.9 μg/mL), while 11 had antibacterial activity toward B. subtilis with an MIC value of 9.70 μg/mL [46]. The novel depside, PS-990 (47), produced by Acremonium sp., had antibacterial potential against B. subtilis, with an MIC value of 0.65 µg/mL and weak activity against E. faecium and S. aureus (MICs 21.0 and 10.0 µg/mL, respectively) [66]. Compound 49 prohibited the formation of peptidoglycan in the in vitro assay, with an IC50 value of 5 µg/mL in E. faecalis (strain A256) compared with a panel of antibiotics, suggesting that it interfered with cell wall trans-glycosylation [90].
The endophytic fungus Cladosporium uredinicola, isolated from Psidium guajava fruits, produced 9, 10, 80, and 81. The metabolites 9, 80, and 81 were assessed against S. aureus, E. coli, P. aeruginosa, and B. subtilis. Compound 9 inhibited the growth of P. aeruginosa and B. subtilis, with MIC values of 25 µg/mL, and E. coli and S. aureus, with MIC values of 250 µg/mL. On the other hand, 80 displayed a bacteriostatic effect (dose of 250 µg/mL) toward all tested bacteria, while 81 had a bacteriostatic effect for S. aureus and E. coli at a dose of 250 µg/mL and at a dose of 25 µg/mL for P. aeruginosa and B. subtilis [49]. Moreover, 86 and 88–90 had antibacterial activity against B. subtilis, with IZDs ranging from 7 to 11 mm; however, they were inactive against Saccharomyces sake, P. aeruginosa, E. coli, Mycobacterium smegmatis, Micrococcus luteus, Pyricularia oryzae, S. aureus, C. albicans, Mucor racemosus, and A. niger with the paper-disk method [74]. In the disk diffusion method, compound 91, biosynthesized by Humicola sp., possessed no antimicrobial capacity against B. subtilis, M. smegmatis, S. sake, M. luteus, P. aeruginosa, E. coli, M. racemosus, S. aureus, A. niger, P. oryzae, and C. albicans [76].

3.3. Antifouling Activity

The anti-larval settlement activities of 15, 48, 56, 58, 59, and 70–79 were assessed towards cyprid larvae of B. amphitrite [52]. Compounds 15, 48, 56, 71–73, and 76–78 deterred larval settlement, with EC50s ranging from 2.95 to 69.19 µM in comparison to butenolide (EC50 4.62 µM). At a concentration of 10 µM, 15, 71–73, and 77 exhibited narcotic potential toward B. amphitrite cyprids. They caused the loss of the phototactic response of cyprids, in addition to decreasing the appendage activity and cyprids becoming completely immobilized. The recovery rates of cyprids treated with 15, 71–73, and 77 (concentration of 10 µM) revealed that larvae possessed the highest recovery rate after treatment with 71, while no larvae recovered after treatment with 15 for 24 h. From all tested compounds, 71 had an excellent antifouling potential and cyprids treated with it had the highest recovery rate. Thus, 71, 72, and 77 were reversible inhibitors. Conversely, 58–59, 74, and 75 had no effect [52].

3.4. Anti-Diabetic Activity

Diabetes is among the most prevalent chronic diseases and is characterized by hyperglycemia, which leads to damage of the blood vessels. This may produce macro- and micro-vascular disorders, as well as other complications, such as sexual dysfunction, dementia, lower-limb amputations, and depression [91]. Diabetes prevalence is expected to be at approximately 366 million cases by the year 2030 [92]. The side effects of the available hypoglycemic agents necessitate the discovery of efficient, low-side-effect, and affordable agents for treating diabetes.
Rivera-Chávez et al. reported that the tridepside, 59 (dose 3.1–31.6 mg/kg), reduced glucose blood levels after 30 min of oral administration of the sucrose load in mice (3.0 g/kg); however, only the highest dose (31.6 mg/kg) caused a marked reduction in blood glucose levels in NA-STZ (nicotinamide-streptozotocin) diabetic mice, indicating that 59 (doses of 3.1 and 10 mg/kg) reduced the blood glucose levels in both diabetic and normal mice [67].

3.5. D-Glucose-6-Phosphate Phosphohydrolase Inhibitory Activity

G6Pase (D-glucose-6-phosphate phosphohydrolase) is a hepatic metabolism-regulating enzyme, that catalyzes the last steps of glycogenolysis and gluconeogenesis pathways [93]. Its inhibition decreases the output of hepatic glucose from both pathways, leading to lowering the blood glucose levels in diabetes. The tetra-depside, 97 isolated from Chloridium sp. CL48903 prohibited G6Pase in rat liver microsomes (IC50 1.6 µM) at a concentration of 133 µM, using a colorimetric assay and hepatocyte glucose output (81% inhibition), indicating the role of 97 as a G6Pase inhibitor [77].

3.6. α-Glucosidase Inhibitory (αGI) Activity

The α-glucosidase enzyme is an important therapeutic target for treating carbohydrate-mediated diseases. It catalyzes the breakdown of oligo- and disaccharides into monosaccharides in the final stage of carbohydrate digestion, leading to a rise in glucose levels [94,95,96,97]. Several studies revealed that α-glucosidase inhibitors (αGIs) slow down the digestion and absorption of carbohydrates, and thus reduce the postprandial blood glucose level [94,95,96,97]. The serious side effects of the current αGIs, such as liver injuries and gastrointestinal damage, have directed research efforts toward discovering and developing new and safer anti-diabetic agents.
Stereum hirsutum produced isoprenylated depsides; 17–23, 38–40, and 42–44, which possessed an αGI capacity with IC50 values ranging from 3.06 to 36.64 µM, in comparison to acarbose (IC50 640.88 µM). Compounds 21 and 42 had no αGI activity (IC50 > 50 µM). Compounds 17–19 displayed stronger αGI activities than 20–23, revealing that ring-B substitution with carbonyl functionality can increase activity. Furthermore, 17 showed much stronger activity than 16, confirming that the isoprenyl group strongly influences the activity. However, furan ring formation at C-2 and C-3 in 16, and C-8 connectivity of a propane-1,2,3-triol moiety in 21, greatly reduced activity levels [53]. Compounds 11, 45, and 46 exhibited significant αGI activity, with IC50 values of 60.20, 36.2, and 35.80 μM, respectively, compared to 1-deoxynojirimycin (62.8 μM), in the colorimetric α-glucosidase assay [46]. The tridepsides, 48, 58, and 59, exhibited higher Saccharomyces cerevisieae α-glucosidase (αGHY) inhibitory activity, with IC50 values of 23.8, 15.8, and 22.1 µM, respectively, than acarbose (IC50 545 µM). They are considered non-competitive inhibitors with Ki values of 27.8–66.2 µM. On the other hand, 58 prohibited the activity of αGHBs (α-glucosidase from Bacillus stearothermophilus), with an IC50 of 30.5 µM, which was less active than acarbose (IC50 0.015 µM) [67].

3.7. Protein Tyrosine Phosphatase Inhibitory (PTP1BI) Activity

PTP1B (protein-tyrosine phosphatase 1B) is a negative regulator of the insulin signaling pathway. The inhibition of PTP1B activity has great promise for alleviating insulin and leptin resistance; hence, PTP-1BIs (PTP1B inhibitors) show potential for treating T2DM and other metabolic disorders [98].
Cosmospora sp. produced aquastatin A (32) (IC50 0.19 µM) that showed modest but selective PTP1BI activity over other PTPs (protein tyrosine phosphatases) such as TCPTP (T-cell protein tyrosine phosphatase) (IC50 0.51 µM), SHP-2 (IC50 > 44 µM), CD45 (IC50 > 44 µM), and LAR (IC50 > 44 µM), compared with ursolic acid (IC50 2.5 µM). It was suggested that the 2,4-dihydroxy-6-pentadecylbenzoic acid moiety is critical for PTP1BI activity [60].

3.8. Diacylglycerol Acyltransferase Inhibitory (DGATI) Activity

Postprandial hypertriglyceridemia is considered the main risk factor for cardiovascular functions. Thus, triglyceride synthesis inhibition has remarkable therapeutic potential in metabolic disorder treatment. The enzymes known as diacylglycerol acyltransferases (DGATs) catalyze the final and only committed step in the biosynthesis of triglycerides [99]. Therefore, these enzymes could be a potential therapeutic target to combat cardio-metabolic disorders [71,82,99]. Compound 9 also inhibited TG synthesis (IC50 91 µM), as well as PC and PE syntheses, indicating that it had a non-specific DGATI effect [76]. The compounds 86 and 88–90 were purified from Humicola sp. by Tomoda et al. [74]. Compound 88 was the most potent DGATI, with an IC50 of 10.2 µM, followed by 86 (IC50 17.5 µM), 89 (IC50 19.2 µM), and 90 (IC50 51.6 µM). They also inhibited the formation of triacylglycerol using Raji cells on the intact cell assay, with IC50 values ranging from 2.82 to 17.2 µM. At high concentrations, 86 moderately inhibited the formation of phosphatidylethanolamine (PE) and phosphatidylcholine (PC), whereas 89 possessed a weak effect, indicating that 89 specifically suppressed the formation of triacylglycerol (TG) [74]. Moreover, 91, when isolated from Humicola sp. FO-5969, showed a dose-dependent inhibition of DGAT using rat liver microsomes in the enzyme assay. At an IC50 124 µM, it was weaker than 88 (IC50 10.2 µM), revealing the fact that the 11-OH group was important for potent DGAT-I. Inokoshi et al. purified from Humicola sp. six new tridepsides, 87 and 92–96, as well as the known metabolites, 86 and 88–90 [71]. In the enzyme assay, utilizing microsomal fractions prepared from S. cerevisiae expressing human DGAT-2 and DGAT-1, the non-glycoside compound 96 inhibited DGAT-1 and DGAT-2 with an IC50 value of 40 µM, whereas the glycosylated metabolites 92–95 had no and/or very weak DGATI potential, suggesting that the sugar moiety at C-11 reduced the DGATI. However, the compounds 86 and 88–90 were dual DGATIs, with IC50 values ranging from 20 to 170 µM for DGAT-1 and 30–170 µM for DGAT-2 [71,82].

3.9. Activity of 11β-Hydroxysteroid Dehydrogenase Inhibitory (11β-HSDI) Enzyme

High levels of glucocorticoid produce insulin resistance and glucose intolerance, leading to metabolic syndrome (MS) [100]. The enzyme 11β-HSD (11β-hydroxysteroid dehydrogenase) is accountable for the production of glucocorticoids in tissues, thus it plays a remarkable role in T2DM and MS. The 11β-HSD1 inhibitors (11β-HSD1Is) could be considered promising therapeutics in treating MS. Compounds 38–41 exhibited powerful and selective inhibitory activities against 11β-HSD1 in the HTRF immunoassay. They inhibited human 11β-HSD1 activity in a dose-dependent manner with IC50 values ranging from 240 to 6600 nM. Compounds 38 and 40 were the most active with IC50s 240 and 230 nM, respectively, while they did not prohibit 11β-HSD2 (IC50 > 10,000 nM) [64].

3.10. Anti-Inflammatory Activities

Inflammation is a beneficial and complicated immune system response to tissue damage or external challenges [101]. Prolonged uncontrolled inflammation leads to various diseases, such as cancer, diabetes, and neurodegenerative and cardiovascular disorders, due to the expression of various inflammatory mediators [102]. The anti-inflammatory potential was estimated by assessing the suppression of pro-inflammatory cytokine expression (e.g., IL-6, TNF-α, and IL-1β), pro-inflammatory enzymes (e.g., iNOS, COX-2), derived production (PGE2 and NO), and various inflammatory signal pathways in immune monocytes and macrophages (e.g., RAW264.7 cells, BV2 cells), whether in vitro, stimulated by LPS (lipopolysaccharide) [103], or by the inhibited swelling rate in a mouse ear edema model in vivo [104].
Compound 23, biosynthesized by Stereum hirsutum, exhibited noticeable NO inhibitory potential (IC50 19.17 µM) in the LPS-induced macrophages, compared with hydrocortisone (IC50 48.15 µM) [40]. Moreover, 48 (ID50 12 µM) and 49 (ID50 9 µM) possessed considerable anti-inflammatory potential for the conversion of 14C-arachidonic acid into PGF2α plus PGE2 by the microsomes of ram seminal vesicles [69,81]. ID50s of the conversion of arachidonic acid (AA) into PGH2 (prostaglandin H2), PGH2 into (prostaglandin E2), and thromboxane A2 (TXA2) synthetase are 10, 40, 150 µM, respectively, for 48 in comparison to indomethacin (ID50 30 for PGH2 and 130 µM for PGE2) and imidazole (ID50 200 µM for TXA2 synthetase); meanwhile, 49 had ID50 values of 40, 9, and 350 µM, respectively. Compound 48 had a strong inhibitory effect on the conversion of AA into PGH2, while 49 specifically inhibited the step involving PGE2 synthesis from PGH2. Moreover, they inhibited TXA2 synthesis in bovine platelet microsomes (ID50 values of 150 and 350 µM, respectively), which was comparable to imidazole (200 µM) [69,81]. Both compounds (dose 50 mg/kg, orally) showed no significant anti-inflammatory effects on carrageenan-induced edema in rats. However, 49 caused a 70% inhibition of this edema system at an intravenous (IV) dose of 5 mg/kg, while 48 displayed no activity, even with IV administration [81]. Matsumoto et al. also stated that 8, 49, and 51–53 had powerful rat PLA2-II inhibitory potential (IC50 values ranged from 0.45 to 43 µM) in comparison to manoalide (IC50 2.0 µM) [70], while they had marked capacities toward human PLA2 (phospholipase A2)-II (IC50s 29, 2.4, 2.1, 6.2, and 9.3 µM, respectively) relative to manoalide (IC50 1.5 µM) [70].

3.11. Antimalarial Activity

Malaria is among many prevalent health concerns and is caused by the Plasmodium parasite in several of the world’s tropical regions [105]. The emergence of malaria strains that are drug-resistant to the available therapeutics makes the discovery of new antimalarial agents a great scientific challenge [14,106].
The two new depside galactopyranosides, 28 and 29, and their aglycone 27, isolated from Acremonium sp., were tested against Plasmodium falciparum K1 using a microculture radioisotope technique. Only compound 27 was active towards P. falciparum K1, with an IC50 value of 9.9 µM compared with dihydroartemisinin (IC50 0.0039 µM). However, 28 and 29 had weak effects (IC50 > 10 µM) [41].

3.12. Antioxidant Activity

The depsides, 23 and 24 showed weak radicals scavenging capacity with EC50 > 200 µM [40]. In the DPPH (2-diphenyl-1-picrylhydrazyl) assay, 11, 45, and 46 also had weak antioxidant activity, compared with ascorbic acid [46].

3.13. Ca2+/CaM Dependent Phosphodiesterase Inhibitory (CaM-PDEI) Activity

Calmodulin (CaM) is a prevalent Ca2+-binding protein that regulates several Ca2+-dependent cellular functions in physiological and pathophysiological processes [107]. It is implicated in the cytoskeleton function and architecture, cell motility, apoptosis, cell proliferation, autophagy, the dephosphorylation/phosphorylation of proteins, reproductive processes, ion channel function, the relaxation/contraction of smooth muscle, and gene expression [108]. CaM can regulate these processes via modulating various proteins, including enzymes: phosphodiesterase, kinases, NOS (nitric oxide synthases), phosphatases, and ion channels. CaM-PDE is a key enzyme that is embroiled in the complex interactions between the cyclic nucleotide and Ca2+-second messenger systems [108]. Moreover, CaM is linked with several pathological states, including smooth muscle malfunctions and unregulated cell growth. CaM-PDEIs may play an important role in treating various disorders, such as neurodegenerative diseases and cancer [109].
Nakanishi et al. reported that 34 and 35, purified from Sporothrix sp., inhibited heart and bovine brain PDEs (IC50 4.3 and 1.8 µM and 5.9 and 15.0 µM, respectively) [63]. Moreover, they prohibited the CaM-dependent activities of CaM-PDEs but had a low effect against their CaM-independent effects, suggesting that these compounds interacted with CaM to inhibit Ca2+/CaM-dependent enzymes. On the other hand, they had no inhibitory activities on protein kinase C [63]. Moreover, PS-990 (47), isolated from Acremonium sp., inhibited brain CaM-PDE with an IC50 value of 3 µg/mL and did not elevate the intracellular cyclic AMP level. It markedly induced the neurite extension of Neuro2A (mouse neuroblastoma) at concentrations ranging from 10 to 30 µg/mL, suggesting its neuritogenic effect. It inhibited both cell growth and thymidine incorporation into the cells at the same concentration range. Interestingly, 47 reversibly induced neurite formation, with cell growth arrest through a mechanism other than increasing the intracellular cyclic AMP concentration [66,110].

3.14. Antiviral Activity

HCMV (human cytomegalovirus) is the most familiar viral cause of congenital infections, which can lead to severe birth defects. Its current treatments include viral DNA polymerase inhibitors, which block the late stages of HCMV replication; however, they do not prohibit the viral induction of multiple cell activation events [111]. Thus, it may be beneficial to discover new treatments for HCMV infections.
Compounds 27–29 were assessed against HSV-1 (Herpes simplex virus type 1), using the SBR technique. Only 28 showed potent activity, with an IC50 value of 7.2 µM, compared with acyclovir (IC50 10.2 µM), while 27 and 29 displayed weak activity, with IC50 values of > 1000 and > 50 µM, respectively [41]. Cytonaema sp. yielded novel p-tridepsides; 84 and 85 showed in vitro inhibitory activities to hCMV protease, with IC50 values of 43 and 11 µM, respectively, in the scintillation proximity assay [73].

3.15. Human Leukocyte Elastase (HLE) Inhibitory Activity

HLE is one of the most destructive enzymes that can degrade tissue matrix proteins, such as collagen, elastin, fibronectin, proteoglycan, and laminin, by activating progelatinase, procollagenase, and prostromelysin [25]. It is released from PMNLs (polymorphonuclear leukocytes) as a result of inflammatory mediators and stimuli. HLE is considered an important therapeutic target for treating many inflammation-linked disorders [112].
The depsides, 25 (IC50 45.1 µM) and 26 (IC50 92.6 µM), weakly inhibited HLE in the spectro-photometric immunoassay, while the tridepside, 83 (IC50 1.8 µM), exhibited high HLE inhibitory activity compared to ulinastatin (IC50 1.1 µg/mL), which was 25–50-fold greater than that of depsides [25].

3.16. Indoleamine 2,3-Dioxygenase Inhibitory (IDOI) Activity

IDO (indoleamine 2,3-dioxygenase) catalyzes the tryptophan catabolism initial step via the KP (kynurenine pathway) [68]. Dysregulation of the KP is accompanied by the IDO activity elevation and production of quinolinic acid (an excitotoxin), which has been engaged in the pathogenesis of neurodegenerative disorders, neuroinflammatory, HIV encephalitis, age-related cataract, and depression [68]. Therefore, IDO is a promising target of new therapeutics for treating neurological disorders and cancer, as well as other disorders characterized by a defect in tryptophan metabolism.
Compounds 49, 54, and 65 isolated from Coniochaeta sp., inhibited the activity of IDO with IC50 values of 21.2, 14.5, and, 26 µM, respectively in comparison to menadione (IC50 3.7 µM) [68].

3.17. Adenosine Triphosphatase Inhibitory Activity

Na+/K+-ATPase (sodium/potassium adenosine triphosphatase) is an integral membrane protein that is accountable for maintaining Na+ and K+ gradients across the plasma membrane, an important process for mammalian cell survival. Currently, it is extensively studied as a potential target for cancer treatment, especially in glioblastoma and lung cancer [113]. The proton pump, H+/K+ ATPase, plays an important role in the stomach acidification process. Its inhibition in gastric parietal cells decreases gastric acid overproduction [114]. H+/K+ ATPase inhibitors can be utilized as a target for developing drugs against gastric acid production disturbances.
Aquastatin A (32) was biosynthesized by Fusarium aquaeductuum. It inhibited Na+/K+-ATPase (adenosine triphosphatase) (IC50 7.1 µM) and H+/K+-ATPase (IC50 6.2 µM) [59].

3.18. Proteasome Inhibitory Activity

Proteasome comprises one or two 19S RPs (regulatory particles) and 20S CPs (core particles). In humans, the 20S CP formation is assisted by proteasome-specific chaperones: PAC1–PAC4 and POMP (proteasome maturation protein) [115,116]. Proteasome accounts for misfolded, unneeded, or damaged cellular protein degradation. Therefore, it is a crucial target for the future treatment of various diseases, such as neurodegenerative and autoimmune diseases, cystic fibrosis, cancer, diabetes, and atherosclerosis [115]. The compound 105 (IC50 0.020 µM) had a potent PAC3 (proteasome-assembling chaperone 3 homodimer) inhibitory effect, while 103 and 107 (IC50 > 250 µM) did not inhibit the PAC3 homodimer [116].

3.19. Phospholipase Inhibitory Activities

Phospholipase A2 (PLA2) catalyzes the hydrolysis of membrane phospholipids into arachidonic acid; therefore, its inhibitors have the potential for treating various inflammatory disorders [117]. Compound 107 showed a strong reversible and noncompetitive inhibition of human PLA2-II (Ki value of 0.098 μM, IC50 value of 0.076 μM); however, it showed weak inhibition of human PLA2-I (IC50 of 18 μM). Its inhibitory effect toward PLA2-II human and PLA2 Naja mocambique was noticeably reduced by methylation of the two COOH groups. Furthermore, 107, upon co-injection with carrageenan, remarkably reduced PLA2 activity and exudate volume in the carrageenan-induced pleurisy rat model [80]. Rat PLA2-II was the most sensitive to 99, with an IC50 of 0.0033 µM and Ki of 0.0068 µM. Furthermore, it showed 50% quenching of the PLA2 of Naja naja venom [78,83]. The metabolites, 48–53, 98–101, and 104–107, purified from T. terricola RF-143, were tested for PLA2 inhibition [70,78]. Compound 99 (IC50 0.0033 μM) was the most potent inhibitor against rat PLA2-II, and the other compounds had inhibitory effects, with an IC50 of 0.0078–0.070 μM. Compounds 48–53 showed strong inhibition toward human PLA2 (phospholipase A2)-II and rat PLA2-II, with IC50s of 2.1–29 µM and 0.45–43 µM, respectively, compared to manoalide (IC50s 1.5 µM and 2.0 µM, respectively) [70]. Moreover, 99 inhibited the histamine release from PLA2-stimulated mast cells. In addition, 99 (IC50 1.4 μM) inhibited bee venom PLA2. The co-injection of 99 (1 μg/paw) with bee venom PLA2 reduced edema formation by 44.7%, via the inhibition of PLA2 activity [84]. It was reported that 99 repressed various secretagogues for stimulated degranulation in rat and mouse mast cells, without affecting PGD2 (prostaglandin D2) synthesis. Thus, the secretory PLA2 inhibition by 99 attenuated the severity of inflammation via repression of the degranulation process [118,119].

4. Conclusions

Recently, more focus has been given to fungi as they are excellent platforms for the biosynthesis of a huge number of structurally diverse metabolites. The knowledge of these metabolites offers a virtually untapped source of new bioactive metabolites with potential agrochemical and pharmaceutical uses. Fungi use these metabolites for defense, and many of these metabolites demonstrate a broad range of bioactivities. Among these metabolites are depsides that possess remarkable bioactivities. According to the listed results, there are 110 depsides that have been isolated from fungi. Most of them are reported from Thielavia (26.6%), Stereum (17.4%), Chaetomium (15%), and Humicola (12%) species (Figure 15).
Thielavia, Chaetomium, and Humicola belong to the Chaetomiaceae family; therefore, this family could be considered as one of the major producers of depsides. It is obvious that the largest number of depsides was isolated in 2002 (18 depsides), 2014 (17 depsides), 2017 (16 depsides), and 1995 (14 depsides) (Figure 16).
Most of the reported depsides have been evaluated for their α-GI (α-glucosidase inhibitory), antimicrobial, antitumor, antifouling, PLA2 (phospholipase A2), and DGATI (diacylglycerol acyltransferase inhibitory) abilities (Figure 17). Thus, these studies revealed that fungal depsides are a rich source for the discovery of effective and novel pharmaceutical leads and should be further exploited.
They also demonstrate inhibitory activities against various enzymes that can be utilized as targets for the treatment of various diseases. These metabolites could have potential as lead compounds for treating metabolic syndrome, obesity, and diabetes via the inhibition of various enzymes, such as HSD, PTP1BI, α-GI, G6Pase, and DGAT. However, extensive explorations of their mechanism of action, as well as structure modification, chemical synthesis, and structure/activity relationship analysis are needed. Despite the extensive structural diversity of depsides, none of them has been approved by the FDA, and none of them has as yet progressed to clinical trials. Therefore, the impact of fungal depsides on human health concerns has to be considered in several ways.

Supplementary Materials

The following are available online at https://www.mdpi.com/article/10.3390/metabo11100683/s1, Table S1: Physical and spectral data of fungal depsides.

Author Contributions

Conceptualization, S.R.M.I. and G.A.M.; resources, G.A.M., S.R.M.I., and S.G.A.M.; discussion of the contents, A.S. and B.G.E., writing—original draft preparation, S.R.M.I., G.A.M., and S.G.A.M., writing—review and editing, G.A.M., S.R.M.I., A.S. and B.G.E. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

ACP: acyl carrier protein; AT: acyl transferase; 11 β-HSD1; 11 β-hydroxysteroid dehydrogenase type 1; 11 β-HSD2:11 β-hydroxysteroid dehydrogenase type 2; 5-FU: 5-fluorouracil; APPIHRMS: atmospheric pressure photoionization high-resolution; B16-F10: murine melanoma cell line; BC: human breast cancer; BT-474: ductal carcinoma; CaM: Calmodulin; CaM-PDE: calmodulin-dependent cyclic-nucleotide phosphodiesterase; CaM-PDEI: Ca2+/CaM dependent phosphodiesterase inhibitory; CCF-STTG1: human astrocytoma cells; CCF-STTG1: human astrocytoma; CD45: leucocyte common antigen; CTC: 5-cyano-2,3-bis(4-methylphenyl)-2H-tetrazolium chloride; DGAT; diacylglycerol acyltransferase; DGATI: diacylglycerol acyltransferase inhibitory; DPPH: 2-diphenyl-1-picrylhydrazyl; EC50: Inhibition of settlement of 50% of the larval population; FSW: filtered sea water; G6Pase: D-glucose-6-phosphate phosphohydrolase; H+/K+ ATPase: hydrogen/potassium adenosine triphosphatase; H46: human non-small cell lung carcinoma; hCMV: human cytomegalovirus; HCT-116: colorectal carcinoma; HepG2: human liver cancer cells: HLE: human leukocyte elastase; HSV-1: Herpes simplex virus type 1; HTRF: homogeneous time resolved fluorescence; IC50: concentration required to inhibit cell growth by 50%; IC: immunocytochemistry and binding; ID50: dose producing a 50% inhibition; IDO: indoleamine 2,3-dioxygenase; IDOI: indoleamine 2,3-dioxygenase inhibitory; IMR-32: neuroblastoma; ISCID: collision-induced dissociation; IZDs: inhibition zone diameters; KB: human epidermoid carcinoma cell; KS: ketosynthase; LAR: leukocyte common antigen-related; MBCs: minimal bactericidal concentrations; CMeT: methyl transferase; MCF-7: human breast adenocarcinoma; MFC: minimal fungicidal concentration; MRSA: methicillin-resistant S. aureus; MS: metabolic syndrome; MTT: (3-(4,5-dimethylthiazol-2-yl))-2,5-diphenyl-2H-tetrazolium bromide; NA-STZ: nicotinamide-streptozotocin; Na+/K+-ATPase: sodium/potassium adenosine triphosphatase; NCI-H187: small-cell lung cancer; PC: phosphatidylcholine; PE: phosphatidylethanolamine; PKSs: polyketide synthases; NR-PKSs: non-reducing polyketide synthases PLA2II: phospholipase A2; PMNLs: polymorphonuclear leukocytes; pNPP: p-nitrophenyl phosphate; PTP1B: protein-tyrosine phosphatase 1B; PTP-1BIs: PTP1B inhibitors; SAM: S-adenosylmethionine; SF268: human astrocytoma: SHP-2: Src homology phosphatase-2; SPA: scintillation proximity assay; SRB: sulforhodamine B; T2DM: type 2 diabetes mellitus; TCPTP: T-cell protein tyrosine phosphatase; TXA2: thromboxane A2; Vero: African green monkey kidney fibroblast; αGHBs: Bacillus stearothermophilus α-glucosidase; αGHY: Saccharomyces cerevisiae α-glucosidase.

References

  1. Hawksworth, D.L.; Lücking, R. Fungal diversity revisited: 2.2 to 3.8 million species. Microbiol. Spect. 2017, 5, 79–95. [Google Scholar] [CrossRef]
  2. Al-Rabia, M.W.; Mohamed, G.A.; Ibrahim, S.R.M.; Asfour, H.Z. Anti-inflammatory ergosterol derivatives from the endophytic fungus Fusarium chlamydosporum. Nat. Prod. Res. 2020, 11, 1–10. [Google Scholar] [CrossRef]
  3. Noor, A.O.; Almasri, D.M.; Bagalagel, A.A.; Abdallah, H.M.; Mohamed, S.G.A.; Mohamed, G.A.; Ibrahim, S.R.M. Naturally occurring isocoumarins derivatives from endophytic fungi: Sources, isolation, structural characterization, biosynthesis, and biological activities. Molecules 2020, 25, 395. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Hyde, K.D.; Xu, J.; Rapior, S.; Jeewon, R.; Lumyong, S.; Niego, A.G.T. The amazing potential of fungi: 50 ways we can exploit fungi industrially. Fungal Divers. 2019, 97, 1–136. [Google Scholar] [CrossRef] [Green Version]
  5. Khayat, M.T.; Ibrahim, S.R.M.; Mohamed, G.A.; Abdallah, H.M. Anti-inflammatory metabolites from endophytic fungus Fusarium sp. Phytochem. Lett. 2019, 29, 104–109. [Google Scholar] [CrossRef]
  6. Sanchez, S.; Demain, A.L. Bioactive products from fungi. Food Bioact. 2017, 59–87. [Google Scholar]
  7. Dias, D.A.; Urban, S.; Roessner, U. A historical overview of natural products in drug discovery. Metabolites 2012, 2, 303–336. [Google Scholar] [CrossRef] [Green Version]
  8. Ibrahim, S.R.M.; Mohamed, G.A.; Kamal, H.M.K.; Mohamed, S.G.A.; Khedr, A.I.M. Terretonins from Aspergillus genus: Structures, biosynthesis, bioactivities, and structural elucidation. Mini-Rev. Org. Chem. 2021, 21, 2654. [Google Scholar] [CrossRef]
  9. Ibrahim, S.R.M.; Altyar, A.E.; Mohamed, S.G.A.; Mohamed, G.A. Genus Thielavia: Phytochemicals, industrial importance and biological relevance. Nat. Prod. Res. 2021, 5, 1–16. [Google Scholar] [CrossRef]
  10. Ibrahim, S.R.M.; Mohamed, S.G.A.; Sindi, I.; Mohamed, G.A. Biologically active secondary metabolites and biotechnological applications of species of the family Chaetomiaceae (Sordariales): An updated review from 2016 to 2021. Mycol. Prog. 2021, 20, 595–639. [Google Scholar] [CrossRef]
  11. Ibrahim, S.R.M.; Mohamed, S.G.A.; Altyar, A.E.; Mohamed, G.A. Humicola genus: Chemical constituents, industrial importance, and biological activities. Curr. Microbiol. 2021, 78, 2488–2509. [Google Scholar] [CrossRef]
  12. Ibrahim, S.R.M.; Mohamed, G.A.; Al Haidari, R.A.; El-Kholy, A.A.; Zayed, M.F.; Khayat, M.T. Biologically active fungal depsidones: Chemistry, biosynthesis, structural characterization, and bioactivities. Fitoterapia 2018, 129, 317–365. [Google Scholar] [CrossRef]
  13. Ibrahim, S.R.M.; Abdallah, H.M.; Elkhayat, E.S.; Al Musayeib, N.M.; Asfour, H.Z.; Zayed, M.F.; Mohamed, G.A. Fusaripeptide A: New antifungal and anti-malarial cyclodepsipeptide from the endophytic fungus Fusarium sp. J. Asian Nat. Prod. Res. 2018, 20, 75–85. [Google Scholar] [CrossRef]
  14. Ibrahim, S.R.M.; Mohamed, G.A.; Al Haidari, R.A.; El-Kholy, A.A.; Zayed, M.F. Potential anti-malarial agents from endophytic fungi: A review. Mini. Rev. Med. Chem. 2018, 18, 1110–1132. [Google Scholar] [CrossRef]
  15. Ibrahim, S.R.M.; Mohamed, G.A.; Al Haidari, R.A.; El-Kholy, A.A.; Asfour, H.; Zayed, M.F. Fusaristerol A: A new ergosterol fatty acid ester from the endophytic fungus Fusarium sp. Pharmacog. Magaz. 2018, 14, 308–311. [Google Scholar] [CrossRef]
  16. Keller, N.P. Fungal secondary metabolism: Regulation, function and drug discovery. Nat. Rev. Microbiol. 2019, 17, 167–180. [Google Scholar] [CrossRef]
  17. Hoffmeister, D.; Keller, N.P. Natural products of filamentous fungi: Enzymes, genes, and their regulation. Nat. Prod. Rep. 2007, 24, 393–416. [Google Scholar] [CrossRef] [PubMed]
  18. Stocker-Wörgötter, E. Metabolic diversity of lichen-forming ascomycetous fungi: Culturing, polyketide and shikimate metabolite production, and PKS genes. Nat. Prod. Rep. 2008, 25, 188–200. [Google Scholar] [CrossRef] [PubMed]
  19. De Medeiros, L.S.; Abreu, L.M.; Nielsen, A.; Ingmer, H.; Larsen, T.O.; Nielsen, K.F.; Rodrigues-Filho, E. Dereplication-guided isolation of depsides thielavins S-T and lecanorins D-F from the endophytic fungus Setophoma sp. Phytochemistry 2015, 111, 154–162. [Google Scholar] [CrossRef] [PubMed]
  20. Shukla, V.; Joshi, G.P.; Rawat, M.S.M. Lichens as a potential natural source of bioactive compounds: A review. Phytochem. Rev. 2010, 9, 303–314. [Google Scholar] [CrossRef]
  21. Dembitsky, V.M.; Tolstikov, G.A. Halogenated phenol compounds in lichens and fungi. Chem. Sustain. Dev. 2003, 11, 557–565. [Google Scholar]
  22. Seshadri, T.R. A Theory of Biogenesis of Lichen Depsides and Depsidones. Indian Acadademy Sci. 1944, 20, 1–14. [Google Scholar] [CrossRef]
  23. Jin, Q.; Hu, X.; Deng, Y.; Hou, J.; Lei, M.; Ji, H.; Zhou, J.; Qu, H.; Wu, W.; Guo, D. Four New Depsides isolated from Salvia miltiorrhiza and their significant nerve-protective activities. Molecules 2018, 23, 3274. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Li, Q.; Zhang, X.; Cao, J.; Guo, Z.; Lou, Y.; Ding, M.; Zhao, Y. Depside derivatives with anti-hepatic fibrosis and anti-diabetic activities from Impatiens balsamina L. flowers. Fitoterapia 2015, 105, 234–239. [Google Scholar] [CrossRef] [PubMed]
  25. Zheng, Z.; Zhang, S.; Lu, X.; Ma, Y.; Fan, Y.; Shi, Y.; Dong, A.; Duan, B. Trivaric acid, a potent depside human leukocyte elastase inhibitor. Biol. Pharm. Bull. 2012, 35, 2247–2251. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Umezawa, H.; Shibamoto, N.; Naganawa, H.; Ayukawa, S.; Matsuzaki, M.; Takeuchi, T.; Kono, K.; Sakamoto, T. Isolation of lecanoric acid, an inhibitor of histidine decarboxylase from a fungus. J. Antibiot. 1974, 27, 587–596. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Yamamoto, Y.; Nishimura, K.; Kiriyama, N. Transformation of asterriquinone diacetate to asterriquinone monoalkyl ether via its monoacetal. Chem. Pharm. Bull. 1976, 24, 1853–1859. [Google Scholar] [CrossRef] [Green Version]
  28. Legaz, M.E.; de Armas, R.; Vicente, C. Bioproduction of Depsidones for Pharmaceutical Purposes; IntechOpen: Rijeka, Croatia, 2011; Volume 19, pp. 487–508. [Google Scholar]
  29. Muggia, L.; Grube, M. Type III polyketide synthases in lichen mycobionts. Fungal Biol. 2010, 114, 379–385. [Google Scholar] [PubMed]
  30. Schümann, J.; Hertweck, C. Advances in cloning, functional analysis and heterologous expression of fungal polyketide synthase genes. J. Biotechnol. 2006, 124, 690–703. [Google Scholar] [CrossRef]
  31. Rawlings, B. Biosynthesis of polyketides (other than Actinomycete Macrolides). Nat. Prod. Rep. 1999, 16, 425–484. [Google Scholar] [CrossRef]
  32. Elix, J.A. Biochemistry and secondary metabolites. In Lichen Biology; Cambridge University Press: Cambridge, UK, 1996; pp. 154–180. [Google Scholar]
  33. Elix, J.A.; Gaul, K.L. The interconversion of the lichen depsides para- and meta-scrobiculin, and the biosynthetic implications. Aust. J. Chem. 1986, 39, 613–624. [Google Scholar] [CrossRef]
  34. Nagai, H.; Kim, Y.H. Cancer prevention from the perspective of global cancer burden patterns. J. Thorac. Dis. 2017, 9, 448–451. [Google Scholar] [CrossRef]
  35. Ward, Z.J.; Scott, A.M.; Hricak, H.; Atun, R. Global costs, health benefits, and economic benefits of scaling up treatment and imaging modalities for survival of 11 cancers: A simulation-based analysis. Lancet Oncol. 2021, 22, 341–350. [Google Scholar] [CrossRef]
  36. Kornienko, A.; Evidente, A.; Vurro, M.; Mathieu, V.; Cimmino, A.; Evidente, M.; van Otterlo, W.A.; Dasari, R.; Lefranc, F.; Kiss, R. Toward a cancer drug of fungal rrigin. Med. Res. Rev. 2015, 35, 937–967. [Google Scholar] [CrossRef] [PubMed]
  37. Lünne, F.; Niehaus, E.M.; Lipinski, S.; Kunigkeit, J.; Kalinina, S.A.; Humpf, H.U. Identification of the polyketide synthase PKS7 responsible for the production of lecanoric acid and ethyl lecanorate in Claviceps purpurea. Fungal Genet. Biol. 2020, 145, 103481. [Google Scholar] [CrossRef]
  38. Phainuphong, P.; Rukachaisirikul, V.; Phongpaichit, S.; Sakayaroj, J.; Kanjanasirirat, P.; Borwornpinyo, S.; Akrimajirachoote, N.; Yimnual, C.; Muanprasat, C. Depsides and depsidones from the soil-derived fungus Aspergillus unguis PSU-RSPG204. Tetrahedron 2018, 74, 5691–5699. [Google Scholar] [CrossRef]
  39. Kurasawa, S.; Takeuchi, T.; Umezawa, H. Studies on glyoxalase inhibitor: Isolation of a new active agent, MS-3, from a mushroom. Agric. Biol. Chem. 1975, 39, 2003–2008. [Google Scholar] [CrossRef]
  40. Ma, K.; Bao, L.; Han, J.; Jin, T.; Yang, X.; Zhao, F.; Li, S.; Song, F.; Liu, M.; Liu, H. New benzoate derivatives and hirsutane type sesquiterpenoids with antimicrobial activity and cytotoxicity from the solid-state fermented rice by the medicinal mushroom Stereum hirsutum. Food Chem. 2014, 143, 239–245. [Google Scholar] [CrossRef]
  41. Bunyapaiboonsri, T.; Yoiprommarat, S.; Khonsanit, A.; Komwijit, S. Phenolic glycosides from the filamentous fungus Acremonium sp. BCC 14080. J. Nat. Prod. 2008, 71, 891–894. [Google Scholar] [CrossRef]
  42. Perlatti, B.; Lan, N.; Earp, C.E.; AghaAmiri, S.; Vargas, S.H.; Azhdarinia, A.; Bills, G.F.; Gloer, J.B. Arenicolins: C-glycosylated depsides from Penicillium arenicola. J. Nat. Prod. 2020, 83, 668–674. [Google Scholar] [CrossRef]
  43. Ko, H.R.; Kim, B.Y.; Oh, W.K.; Kang, D.O.; Lee, H.S.; Koshino, H.; Osada, H.; Mheen, T.I.; Ahn, J.S. CRM646-A and -B, novel fungal metabolites that inhibit heparinase. J. Antibiot. 2000, 53, 211–214. [Google Scholar] [CrossRef] [Green Version]
  44. Wang, P.; Zhang, Z.; Yu, B. Total synthesis of CRM646-A and -B, two fungal glucuronides with potent heparinase inhibition activities. J. Org. Chem. 2005, 70, 8884–8889. [Google Scholar] [CrossRef]
  45. Asami, Y.; Kim, S.O.; Jang, J.P.; Ko, S.K.; Kim, B.Y.; Osada, H.; Jang, J.H.; Ahn, J.S. CRM646-A, a fungal metabolite, induces nucleus condensation by increasing Ca2+ levels in rat 3Y1 fibroblast cells. J. Microbiol. Biotechnol. 2020, 30, 31–37. [Google Scholar] [CrossRef] [PubMed]
  46. Chen, Y.; Yang, W.; Zou, G.; Chen, S.; Pang, J.; She, Z. Bioactive polyketides from the mangrove endophytic fungi Phoma sp. SYSU-SK-7. Fitoterapia 2019, 139, 104369. [Google Scholar] [CrossRef] [PubMed]
  47. Togashi, K.; Ko, H.R.; Ahn, J.S.; Osada, H. Inhibition of telomerase activity by fungus metabolites, CRM646-A and thielavin B. Biosci. Biotechnol. Biochem. 2001, 65, 651–653. [Google Scholar] [CrossRef] [PubMed]
  48. Ayers, S.; Ehrmann, B.M.; Adcock, A.F.; Kroll, D.J.; Wani, M.C.; Pearce, C.J.; Oberlies, N.H. Thielavin B methyl ester: A cytotoxic benzoate trimer from an unidentified fungus (MSX 55526) from the order Sordariales. Tetrahedron Lett. 2011, 52, 5733–5735. [Google Scholar] [CrossRef] [Green Version]
  49. De Medeiros, L.S.; Murgu, M.; de Souza, A.Q.L.; Rodrigues-Fo, E. Antimicrobial depsides produced by Cladosporium uredinicola, an endophytic fungus isolated from Psidium guajava fruits. Helv. Chim. Acta. 2011, 94, 1077–1084. [Google Scholar] [CrossRef]
  50. Cao, S.; Lee, A.S.; Huang, Y.; Flotow, H.; Ng, S.; Butler, M.S.; Buss, A.D. Agonodepsides a and B: Two new depsides from a filamentous fungus F7524. J. Nat. Prod. 2002, 65, 1037–1038. [Google Scholar] [CrossRef]
  51. Nielsen, J.; Nielsen, P.H.; Frisvad, J.C. Fungal depside, guisinol, from a marine derived strain of Emericella unguis. Phytochemistry 1999, 50, 263–265. [Google Scholar] [CrossRef]
  52. Han, Z.; Li, Y.X.; Liu, L.L.; Lu, L.; Guo, X.R.; Zhang, X.X.; Zhang, X.Y.; Qi, S.H.; Xu, Y.; Qian, P.Y. Thielavins W-Z₇, New Antifouling Thielavins from the Marine-Derived Fungus Thielavia sp. UST030930-004. Mar. Drugs 2017, 15, 128. [Google Scholar] [CrossRef] [Green Version]
  53. Wang, B.T.; Qi, Q.Y.; Ma, K.; Pei, Y.F.; Han, J.J.; Xu, W.; Li, E.W.; Liu, H.W. Depside α-glucosidase inhibitors from a culture of the mushroom Stereum hirsutum. Planta Med. 2014, 80, 918–924. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Nakamura, H.; Iitaka, Y.; Kurasawa, S.; Takeuchi, T.; Umezawa, H. The crystal structure of a dibromo-derivative of MS-3: A glyoxalase I inhibitor produced by a mushroom, Stereum hirsutum. Agric. Biol. Chem. 1976, 40, 1781–1784. [Google Scholar] [CrossRef]
  55. Kurasawa, S.; Naganawa, H.; Takeuchi, T.; Umezawa, H. The structure of MS-3: A glyoxalase I inhibitor produced by a mushroom. Agric. Biol. Chem. 1975, 39, 2009–2014. [Google Scholar]
  56. Yasuzawa, T.; Saitoh, Y.; Sano, H. Structures of KS-501 and KS-502, the new inhibitors of Ca2+ and calmodulin-dependent cyclic nucleotide phosphodiesterase. J. Antibiot. 1990, 43, 336–343. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  57. Aqueveque, P.; Céspedes, C.L.; Becerra, J.; Dávila, M.; Sterner, O. Bioactive compounds isolated from submerged fermentations of the Chilean fungus Stereum rameale. Z. Naturforsch. C. J. Biosci. 2015, 70, 97–102. [Google Scholar] [CrossRef] [PubMed]
  58. Aqueveque, P.; Céspedes, C.L.; Becerra, J.; Aranda, M.; Sterner, O. Antifungal activities of secondary metabolites isolated from liquid fermentations of Stereum hirsutum (Sh134-11) against Botrytis cinerea (grey mould agent). Food Chem. Toxicol. 2017, 109, 1048–1054. [Google Scholar] [CrossRef]
  59. Wang, H.; Yang, Q.; Dou, Q.P.; Yang, H. Discovery of natural proteasome inhibitors as novel anticancer therapeutics: Current status and perspectives. Curr. Protein Pept. Sci. 2018, 19, 358–367. [Google Scholar] [CrossRef]
  60. Seo, C.; Sohn, J.H.; Oh, H.; Kim, B.Y.; Ahn, J.S. Isolation of the protein tyrosine phosphatase 1B inhibitory metabolite from the marine-derived fungus Cosmospora sp. SF-5060. Bioorg. Med. Chem. Lett. 2009, 19, 6095–6097. [Google Scholar] [CrossRef]
  61. Kwon, Y.J.; Fang, Y.; Xu, G.H.; Kim, W.G. Aquastatin A, a new inhibitor of enoyl-acyl carrier protein reductase from Sporothrix sp. FN611. Biol. Pharm. Bull. 2009, 32, 2061–2064. [Google Scholar] [CrossRef] [Green Version]
  62. Sakemi, S.; Hirai, H.; Ichiba, T.; Inagaki, T.; Kato, Y.; Kojima, N.; Nishida, H.; Parker, J.C.; Saito, T.; Tonai-Kachi, H. Thielavins as glucose-6-phosphatase (G6Pase) inhibitors: Producing strain, fermentation, isolation, structural elucidation and biological activities. J. Antibiot. 2002, 55, 941–951. [Google Scholar] [CrossRef] [Green Version]
  63. Nakanishi, S.; Ando, K.; Kawamoto, I.; Kase, H. KS-501 and KS-502, new inhibitors of Ca2+ and calmodulin-dependent cyclic-nucleotide phosphodiesterase from Sporothrix sp. J. Antibiot. 1989, 42, 1049–1055. [Google Scholar] [CrossRef]
  64. Ito-Kobayashi, M.; Aoyagi, A.; Tanaka, I.; Muramatsu, Y.; Umetani, M.; Takatsu, T. Sterenin A, B, C and D, novel 11beta-hydroxysteroid dehydrogenase type 1 inhibitors from Stereum sp. SANK 21205. J. Antibiot. 2008, 61, 128–135. [Google Scholar] [CrossRef]
  65. Zou, W.X.; Meng, J.C.; Lu, H.; Chen, G.X.; Shi, G.X.; Zhang, T.Y.; Tan, R.X. Metabolites of Colletotrichum gloeosporioides, an endophytic fungus in Artemisia mongolica. J. Nat. Prod. 2000, 63, 1529–1530. [Google Scholar] [CrossRef] [PubMed]
  66. Toki, S.; Ando, K.; Yoshida, M.; Matsuda, Y. PS-990, a novel neuritogenic compound from Acremonium sp. J. Antibiot. 1994, 47, 1175–1181. [Google Scholar] [CrossRef] [Green Version]
  67. Rivera-Chávez, J.; González-Andrade, M.; González, M.; Glenn, A.E.; Mata, R. Thielavins A, J and K: α-Glucosidase inhibitors from MEXU 27095, an endophytic fungus from Hintonia latiflora. Phytochemistry 2013, 94, 198–205. [Google Scholar] [CrossRef]
  68. Bejček, J.; Spiwok, V.; Kmoníčková, E.; Rimpelová, S. Na+/K+-ATPase Revisited: On Its Mechanism of Action, Role in Cancer, and Activity Modulation. Molecules 2021, 26, 1905. [Google Scholar]
  69. Matsumoto, K.; Tanaka, K.; Matsutani, S.; Sakazaki, R.; Hinoo, H.; Uotani, N.; Tanimoto, T.; Kawamura, Y.; Nakamoto, S.; Yoshida, T. Isolation and biological activity of thielocins: Novel phospholipase A2 inhibitors produced by Thielavia terricola RF-143. J. Antibiot. 1995, 48, 106–112. [Google Scholar] [CrossRef] [Green Version]
  70. Yang, B.; Huang, J.; Zhou, X.; Lin, X.; Liu, J.; Liao, S.; Wang, J.; Liu, F.A.; Tao, H.; Liu, Y. The fungal metabolites with potential antiplasmodial activity. Curr. Med. Chem. 2018, 25, 3796–3825. [Google Scholar] [CrossRef] [PubMed]
  71. Inokoshi, J.; Takagi, Y.; Uchida, R.; Masuma, R.; Omura, S.; Tomoda, H. Production of a new type of amidepsine with a sugar moiety by static fermentation of Humicola sp. FO-2942. J. Antibiot. 2010, 63, 9–16. [Google Scholar] [CrossRef] [Green Version]
  72. Tomoda, H.; Tabata, N.; Ito, M.; Omura, S. Amidepsines, inhibitors of diacylglycerol acyltransferase produced by Humicola sp. FO-2942. II. Structure elucidation of amidepsines A, B and C. J. Antibiot. 1995, 48, 942–947. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  73. Saleem, M.; Nazir, M.; Hussain, H.; Tousif, M.I.; Elsebai, M.F.; Riaz, N.; Akhtar, N. Natural phenolics as inhibitors of the human neutrophil elastase (HNE) release: An overview of natural anti-inflammatory discoveries during recent years. Antiinflamm. Antiallergy Agents Med. Chem. 2018, 17, 70–94. [Google Scholar] [CrossRef]
  74. Tomoda, H.; Ito, M.; Tabata, N.; Masuma, R.; Yamaguchi, Y.; Omura, S. Amidepsines, inhibitors of diacylglycerol acyltransferase produced by Humicola sp. FO-2942. I. Production, isolation and biological properties. J. Antibiot. 1995, 48, 937–941. [Google Scholar] [CrossRef] [Green Version]
  75. Matsutani, S.; Sakazaki, R.; Hinoo, H.; Terui, Y.; Tanaka, K.; Matsumoto, K.; Yoshida, T. 19 Structural elucidation of thielocins: Novel potent phospholipase A-2 inhibitors from a fungus. Tennen Yuki Kagobutsu Toronkai Koen Yoshishu 1992, 34, 142–149. [Google Scholar]
  76. Tomoda, H.; Yamaguchi, Y.; Tabata, N.; Kobayashi, T.; Masuma, R.; Tanaka, H.; Omura, S. Amidepsine E, an inhibitor of diacylglycerol acyltransferase produced by Humicola sp. FO-5969. J. Antibiot. 1996, 49, 929–931. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  77. Kim, Y.J.; Nishida, H.; Pang, C.H.; Saito, T.; Sakemi, S.; Tonai-Kachi, H.; Yoshikawa, N.; Vanvolkenburg, M.A.; Parker, J.C.; Kojima, Y. CJ-21,164, a new D-glucose-6-phosphate phosphohydrolase inhibitor produced by a fungus Chloridium sp. J. Antibiot. 2002, 55, 121–127. [Google Scholar] [CrossRef] [Green Version]
  78. Tanaka, K.; Matsutani, S.; Matsumoto, K.; Yoshida, T. Effect of thielocin A1 beta on bee venom phospholipase A2-induced edema in mouse paw. Eur. J. Pharmacol. 1995, 279, 143–148. [Google Scholar] [CrossRef]
  79. Nagamitsu, T.; Marumoto, K.; Nagayasu, A.; Fukuda, T.; Arima, S.; Uchida, R.; Ohshiro, T.; Harigaya, Y.; Tomoda, H.; Omura, S. Total synthesis of amidepsine B and revision of its absolute configuration. J. Antibiot. 2009, 62, 69–74. [Google Scholar] [CrossRef] [Green Version]
  80. Tanaka, K.; Matsutani, S.; Matsumoto, K.; Yoshida, T. A novel type of phospholipase A2 inhibitor, thielocin A1 beta, and mechanism of action. J. Antibiot. 1992, 45, 1071–1078. [Google Scholar] [CrossRef] [PubMed]
  81. Kitahara, N.; Haruyama, H.; Hata, T.; Takahashi, S. The structures of thielavins A., B and C. Prostaglandin synthetase inhibitors from fungi. J. Antibiot. 1983, 36, 599–600. [Google Scholar] [CrossRef] [Green Version]
  82. Inokoshi, J.; Kawamoto, K.; Takagi, Y.; Matsuhama, M.; Omura, S.; Tomoda, H. Expression of two human acyl-CoA:diacylglycerol acyltransferase isozymes in yeast and selectivity of microbial inhibitors toward the isozymes. J. Antibiot. 2009, 62, 51–54. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  83. Yoshida, T.; Nakamoto, S.; Sakazaki, R.; Matsumoto, K.; Terui, Y.; Sato, T.; Arita, H.; Matsutani, S.; Inoue, K.; Kudo, I. Thielocins A1 alpha and A1 beta, novel phospholipase A2 inhibitors from ascomycetes. J. Antibiot. 1991, 44, 1467–1470. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  84. Murakami, M.; Kudo, I.; Nakamura, H.; Yokoyama, Y.; Mori, H.; Inoue, K. Exacerbation of rat adjuvant arthritis by intradermal injection of purified mammalian 14-kDa group II phospholipase A2. FEBS Lett. 1990, 268, 113–116. [Google Scholar] [CrossRef] [Green Version]
  85. Davies, J.; Davies, D. Origins and evolution of antibiotic resistance. Microbiol. Mol. Biol. Rev. 2010, 74, 417–733. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  86. Jakubczyk, D.; Dussart, F. Selected fungal natural products with antimicrobial properties. Molecules 2020, 25, 911. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  87. Zhang, Y.M.; White, S.W.; Rock, C.O. Inhibiting bacterial fatty acid synthesis. J. Biol. Chem. 2006, 281, 17541–17544. [Google Scholar] [CrossRef] [Green Version]
  88. Moir, D.T. Identification of inhibitors of bacterial enoyl-acyl carrier protein reductase. Curr. Drug Targets Infect. Disord. 2005, 5, 297–305. [Google Scholar] [CrossRef]
  89. Kwon, Y.J.; Sohn, M.J.; Kim, W.G. Aquastatin C, a new glycoaromatic derivative from Sporothrix sp. FN611. J. Antibiot. 2011, 64, 213–216. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  90. Mani, N.; Sancheti, P.; Jiang, Z.D.; McNaney, C.; DeCenzo, M.; Knight, B.; Stankis, M.; Kuranda, M.; Rothstein, D.M. Screening systems for detecting inhibitors of cell wall transglycosylation in Enterococcus. Cell wall transglycosylation inhibitors in Enterococcus. J. Antibiot. 1998, 51, 471–479. [Google Scholar] [CrossRef] [Green Version]
  91. Forbes, J.M.; Cooper, M.E. Mechanisms of diabetic complications. Physiol. Rev. 2013, 93, 137–188. [Google Scholar] [CrossRef]
  92. Choudhury, H.; Pandey, M.; Hua, C.K.; Mun, C.S.; Jing, J.K.; Kong, L.; Ern, L.Y.; Ashraf, N.A.; Kit, S.W.; Yee, T.S. An update on natural compounds in the remedy of diabetes mellitus: A systematic review. J. Tradit. Complement. Med. 2017, 8, 361–376. [Google Scholar] [CrossRef]
  93. Van Schaftingen, E.; Gerin, I. The glucose-6-phosphatase system. Biochem. J. 2002, 362, 513–532. [Google Scholar] [CrossRef]
  94. Ibrahim, S.R.M.; Mohamed, G.A.; Zayed, M.F.; Ross, S.A. 8-Hydroxyirilone 5-methyl ether and 8-hydroxyirilone, new antioxidant and α-amylase inhibitors isoflavonoids from Iris germanica rhizomes. Bioorg. Chem. 2017, 70, 192–198. [Google Scholar] [CrossRef] [PubMed]
  95. Ibrahim, S.R.M.; Mohamed, G.A.; Khayat, M.T.; Ahmed, S.; Abo-Haded, H.; Alshali, K.Z. Mangostanaxanthone VIIII, a new xanthone from Garcinia mangostana pericarps, α-amylase inhibitory activity, and molecular docking studies. Rev. Bras. Farmacogn. 2019, 29, 206–212. [Google Scholar] [CrossRef]
  96. Ibrahim, S.R.M.; Mohamed, G.A.; Khayat, M.T.; Ahmed, S.; Abo-Haded, H. Garcixanthone D, a new xanthone, and other xanthone derivatives from Garcinia mangostana Pericarps: Their α-amylase inhibitory potential and molecular docking studies. Starch-Stärke 2019, 71, 1800354. [Google Scholar] [CrossRef]
  97. Ibrahim, S.R.M.; Mohamed, G.A.; Khayat, M.T.; Ahmed, S.; Abo-Haded, H. α-Amylase inhibitors xanthones from Garcinia mangostana pericarps and its possible use for the treatment of diabetes with their molecular docking studies. J. Food Biochem. 2019, 43, e12844. [Google Scholar] [CrossRef]
  98. Kennedy, B.P. Role of protein tyrosine phosphatase-1B in diabetes and obesity. Biomed. Pharmacother. 1999, 53, 466–470. [Google Scholar] [CrossRef]
  99. King, A.J.; Judd, A.S.; Souers, A.J. Inhibitors of diacylglycerol acyltransferase: A review of 2008 patents. Expert Opin. Ther. Pat. 2010, 20, 19–29. [Google Scholar] [CrossRef]
  100. Ferris, H.A.; Kahn, C.R. New mechanisms of glucocorticoid-induced insulin resistance: Make no bones about it. J. Clin. Invest. 2012, 122, 3854–3857. [Google Scholar] [CrossRef] [PubMed]
  101. Coussens, L.M.; Werb, Z. Inflammation and cancer. Nature 2002, 420, 860–867. [Google Scholar] [CrossRef]
  102. Hotamisligil, G.S. Inflammation, metaflammation and immunometabolic disorders. Nature 2017, 542, 177–185. [Google Scholar] [CrossRef] [PubMed]
  103. Niu, X.; Wang, Y.; Li, W.; Zhang, H.; Wang, X.; Mu, Q.; He, Z.; Yao, H. Esculin exhibited anti-inflammatory activities in vivo and regulated TNF-α and IL-6 production in LPS-stimulated mouse peritoneal macrophages in vitro through MAPK pathway. Int. Immunopharmacol. 2015, 29, 779–786. [Google Scholar] [CrossRef] [PubMed]
  104. Kitahara, N.; Endo, A.; Furuya, K.; Takahashi, S. Thielavin A and B, new inhibitors of prostaglandin biosynthesis produced by Thielavia terricola. J. Antibiot. 1981, 34, 1562–1568. [Google Scholar] [CrossRef] [Green Version]
  105. Nieves, K.; Prudhomme, J.; Le Roch, K.G.; Franzblau, S.G.; Rodríguez, A.D. Natural product-based synthesis of novel anti-infective isothiocyanate- and isoselenocyanate-functionalized amphilectane diterpenes. Bioorg. Med. Chem. Lett. 2016, 26, 854–857. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  106. Martínez-Luis, S.; Pérez-Vásquez, A.; Mata, R. Natural products with calmodulin inhibitor properties. Phytochemistry 2007, 68, 1882–1903. [Google Scholar] [CrossRef] [PubMed]
  107. Mata, R.; Figueroa, M.; González-Andrade, M.; Rivera-Chávez, J.A.; Madariaga-Mazón, A.; Del Valle, P. Calmodulin inhibitors from natural sources: An update. J. Nat. Prod. 2015, 78, 576–586. [Google Scholar] [CrossRef]
  108. Kakkar, R.; Raju, R.V.; Sharma, R.K. Calmodulin-dependent cyclic nucleotide phosphodiesterase (PDE1). Cell Mol. Life Sci. 1999, 55, 1164–1186. [Google Scholar] [CrossRef] [PubMed]
  109. Toki, S.; Yoshida, M.; Ando, K.; Matsuda, Y. PS-990, a novel microbial metabolite, reversibly induces neurite extension in neuroblastoma cells. Biosci. Biotechnol. Biochem. 1995, 59, 1281–1286. [Google Scholar] [CrossRef]
  110. Evers, D.L.; Chao, C.F.; Wang, X.; Zhang, Z.; Huong, S.M.; Huang, E.S. Human cytomegalovirus-inhibitory flavonoids: Studies on antiviral activity and mechanism of action. Antiviral Res. 2005, 68, 124–134. [Google Scholar] [CrossRef]
  111. Guo, B.; Dai, J.R.; Ng, S.; Huang, Y.; Leong, C.; Ong, W.; Carté, B.K. Cytonic acids A and B: Novel tridepside inhibitors of hCMV protease from the endophytic fungus Cytonaema species. J. Nat. Prod. 2000, 63, 602–604. [Google Scholar] [CrossRef]
  112. Jang, J.P.; Jang, J.H.; Oh, M.; Son, S.; Kim, S.M.; Kim, H.M.; Shin, K.S.; Oh, H.; Soung, N.K.; Hong, Y.S. Inhibition of indoleamine 2,3-dioxygenase by thielavin derivatives from a soil fungus, Coniochaeta sp. 10F058. J. Antibiot. 2014, 67, 331–333. [Google Scholar] [CrossRef] [Green Version]
  113. Tjandrawinata, R.R.; Nailufar, F.; Arifin, P.F. Hydrogen potassium adenosine triphosphatase activity inhibition and downregulation of its expression by bioactive fraction DLBS2411 from Cinnamomum burmannii in gastric parietal cells. Int. J. Gen. Med. 2013, 6, 807–815. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  114. Hamano, K.; Kinoshita-Okami, M.; Minagawa, K.; Haruyama, H.; Kinoshita, T.; Hosoya, T.; Furuya, K.; Kinoshita, K.; Tabata, K.; Hemmi, A. Aquastatin A, an inhibitor of mammalian adenosine triphosphatases from Fusarium aquaeductuum. Taxonomy, fermentation, isolation, structure determination and biological properties. J. Antibiot. 1993, 46, 1648–1657. [Google Scholar] [CrossRef] [Green Version]
  115. Ohsawa, K.; Yoshida, M.; Izumikawa, M.; Takagi, M.; Shin-Ya, K.; Goshima, N.; Hirokawa, T.; Natsume, T.; Doi, T. Synthesis and biological evaluation of thielocin B1 analogues as protein-protein interaction inhibitors of PAC3 homodimer. Bioorg. Med. Chem. 2018, 26, 6023–6034. [Google Scholar] [CrossRef] [PubMed]
  116. Folmer, F.; Jaspars, M.; Schumacher, M.; Dicato, M.; Diederich, M. Marine natural products targeting phospholipases A2. Biochem. Pharmacol. 2010, 80, 1793–1800. [Google Scholar] [CrossRef] [Green Version]
  117. Tanaka, K.; Matsutani, S.; Kanda, A.; Kato, T.; Yoshida, T. Thielocin B3, a novel antiinflammatory human group II phospholipase A2 specific inhibitor from ascomycetes. J. Antibiot. 1994, 47, 631–638. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  118. Murakami, M.; Kudo, I.; Suwa, Y.; Inoue, K. Release of 14-kDa group-II phospholipase A2 from activated mast cells and its possible involvement in the regulation of the degranulation process. Eur. J. Biochem. 1992, 209, 257–265. [Google Scholar] [CrossRef]
  119. Dubin, G.M.; Fkyerat, A.; Tabacchi, R. Acetylenic aromatic compounds from Stereum hirsutum. Phytochemistry 2000, 53, 571–574. [Google Scholar] [CrossRef]
Metabolites 11 00683 g001 550
Figure 1. Basic structures of orcinol paradepsides, orcinol metadepsides, β-orcinol paradepsides, β-orcinol metadepsides, and mixed orcinol β-orcinol depsides.
Figure 1. Basic structures of orcinol paradepsides, orcinol metadepsides, β-orcinol paradepsides, β-orcinol metadepsides, and mixed orcinol β-orcinol depsides.
Metabolites 11 00683 g001
Metabolites 11 00683 g002 550
Figure 2. Biosynthesis of depsides [18,28,29,30,31,32,33].
Figure 2. Biosynthesis of depsides [18,28,29,30,31,32,33].
Metabolites 11 00683 g002
Metabolites 11 00683 g003 550
Figure 3. Chemical structures of di-depsides 1–16.
Figure 3. Chemical structures of di-depsides 1–16.
Metabolites 11 00683 g003
Metabolites 11 00683 g004 550
Figure 4. Chemical structures of di-depsides 17–27.
Figure 4. Chemical structures of di-depsides 17–27.
Metabolites 11 00683 g004
Metabolites 11 00683 g005 550
Figure 5. Chemical structures of sugar-containing di-depsides 28–33.
Figure 5. Chemical structures of sugar-containing di-depsides 28–33.
Metabolites 11 00683 g005
Metabolites 11 00683 g006 550
Figure 6. Chemical structures of sugar-containing di-depsides 34–37.
Figure 6. Chemical structures of sugar-containing di-depsides 34–37.
Metabolites 11 00683 g006
Metabolites 11 00683 g007 550
Figure 7. Chemical structures of nitrogen-containing di-depsides 38–44.
Figure 7. Chemical structures of nitrogen-containing di-depsides 38–44.
Metabolites 11 00683 g007
Metabolites 11 00683 g008 550
Figure 8. Chemical structures of tri-depsides 45–54.
Figure 8. Chemical structures of tri-depsides 45–54.
Metabolites 11 00683 g008
Metabolites 11 00683 g009 550
Figure 9. Chemical structures of tri-depsides 55–64.
Figure 9. Chemical structures of tri-depsides 55–64.
Metabolites 11 00683 g009
Metabolites 11 00683 g010 550
Figure 10. Chemical structures of tri-depsides 65–76.
Figure 10. Chemical structures of tri-depsides 65–76.
Metabolites 11 00683 g010
Metabolites 11 00683 g011 550
Figure 11. Chemical structures of tri-depsides 77–87.
Figure 11. Chemical structures of tri-depsides 77–87.
Metabolites 11 00683 g011
Metabolites 11 00683 g012 550
Figure 12. Chemical structures of nitrogen- and sugar-containing tri-depsides 88–96 and tetra-depside 97.
Figure 12. Chemical structures of nitrogen- and sugar-containing tri-depsides 88–96 and tetra-depside 97.
Metabolites 11 00683 g012
Metabolites 11 00683 g013 550
Figure 13. Chemical structures of terta- and penta-depside derivatives 98–105.
Figure 13. Chemical structures of terta- and penta-depside derivatives 98–105.
Metabolites 11 00683 g013
Metabolites 11 00683 g014 550
Figure 14. Chemical structures of penta- and hexa-depside 106–110.
Figure 14. Chemical structures of penta- and hexa-depside 106–110.
Metabolites 11 00683 g014
Metabolites 11 00683 g015 550
Figure 15. Numbers of depsides isolated from different fungal genera.
Figure 15. Numbers of depsides isolated from different fungal genera.
Metabolites 11 00683 g015
Metabolites 11 00683 g016 550
Figure 16. Annual numbers of isolated depsides, from 1975 to 2020.
Figure 16. Annual numbers of isolated depsides, from 1975 to 2020.
Metabolites 11 00683 g016
Metabolites 11 00683 g017 550
Figure 17. Biological activities of isolated depsides and the number of articles.
Figure 17. Biological activities of isolated depsides and the number of articles.
Metabolites 11 00683 g017
Table
Table 1. List of fungal depsides (Fungal source, host, and place).
Table 1. List of fungal depsides (Fungal source, host, and place).
Compound NameFungusHost (Part)Source, PlaceRef.
Lecanoric acid (1)Claviceps purpurea (PKS7) -Culture[37]
Ethyl lecanorate (2)Claviceps purpurea (PKS7) -Culture[37]
Aspergiside A (3)Aspergillus unguis PSU-RSPG204 (BCC56860) -Soil, Surat Thani Province, Thailand[38]
Aspergiside B (4)Aspergillus unguis PSU-RSPG204 (BCC56860) -Soil, Surat Thani Province, Thailand[38]
Aspergiside C (5)Aspergillus unguis PSU-RSPG204 (BCC56860) -Soil, Surat Thani Province, Thailand[38]
Lecanorin D (6)Setophoma sp. (KM288713) Fruits of Psidium guajava Sӓo Carlos local trade, São Paulo state, Brazil[19]
Lecanorin E (7)Setophoma sp. (KM288713) Fruits of Psidium guajava Sӓo Carlos local trade, São Paulo state, Brazil[19]
Lecanorin F (8)Setophoma sp. (KM288713) Fruits of Psidium guajava Sӓo Carlos local trade, São Paulo state, Brazil[19]
3-Hydroxy-2,5-dimethylphenyl 2,4-dihydroxy-3,6-dimethylbenzoate (9)Setophoma sp. (KM288713) Fruits of Psidium guajava Sӓo Carlos local trade, São Paulo state, Brazil[49]
3-Hydroxy-2,4,5-trimethylphenyl 2,4-dihydroxy-3,6-dimethylbenzoate (10)Setophoma sp. (KM288713) Fruits of Psidium guajava Sӓo Carlos local trade, São Paulo state, Brazil[49]
Colletotric acid C (11)Phoma sp. (SYSU-SK-7) Healthy branch of Kandelia candelShankou Mangrove Nature Reserve, Guangxi Province, China[46]
Agonodepside A (12)Fungal strain (F7524) Leaves of Derris thyrsiflora Singapore[50]
Agonodepside B (13)Fungal strain (F7524) Leaves of Derris thyrsiflora Singapore[50]
Guisinol (14)Emericella unguis (isolate 1 (M87-2) Stomolopus meleagrisParia Bay, Venezuela [51]
Emericella unguis (M90B-10)Soft part of an unidentified
mollusc		Paria Bay, Venezuela [51]
Thielavin Z7 (15)Thielavia sp (UST030930-004) -12-d Biofilms developed at the pier of the Hong Kong University of Science and Technology in Port Shelter, Hong Kong, China[52]
Sterenin J (16)Stereum hirsutum (EU851110) -Tibetan mountain[53]
Sterenin E (17)Stereum hirsutum (EU851110) -Tibetan mountain[53]
Sterenin F (18)Stereum hirsutum (EU851110) -Tibetan mountain[53]
Sterenin G (19)Stereum hirsutum (EU851110) -Tibetan mountain[53]
Sterenin H (20)Stereum hirsutum (EU851110) -Tibetan mountain[53]
Sterenin I (21)Stereum hirsutum (EU851110) -Tibetan mountain[53]
MS-3 (22)Stereum hirsutum (EU851110) -Tibetan mountain[39,53,54,55,56]
Stereum rameale (strain 2511) The bark of a dead treeNative forest of Nothofagus species (Nothofagaceae), near Ñuble National Reserve, Ñuble Province, Chile[57,58]
4′-Hydroxy-5′-methoxy-6′-(3″-methyl-2″-butenyl)-phenyl-2,4-dihydroxy-6-methyl-benzoate/
4-Hydroxy-3-methoxy-2-(3-methylbut-2-en-1-yl)phenyl 2,4-dihydroxy-6-methylbenzoate (23)		Stereum hirsutum (AB733150.1) Tibetan Plateau, China[40]
Stereum hirsutum (EU851110) -Tibetan mountain[53]
4′-Hydroxy-6′-(3″-methyl-2″-butenyl)-phenyl-2,4-dihydroxy-6-methyl-benzoate (24)Stereum hirsutum (AB733150.1) -Tibetan Plateau, China[40]
Nordivaricatic acid (25)Fungal strain -Soil, Yunnan Province, China[25]
65-Divarinyl divarate (26)Fungal strain -Soil, Yunnan Province, China[25]
KS-501a (3-Heptyl-5-hydroxyphenyl 2-heptyl-4,6-dihydroxybenzoate) (27)Acremonium sp. (BCC 14080) Palm leafKhao Yai National Park, Nakhon Ratchasima Province, Thailand[41,56]
KS-501a-2-O-β-D-galactopyranose (28)Acremonium sp. (BCC 14080) Palm leafKhao Yai National Park, Nakhon Ratchasima Province, Thailand[41]
KS-501a-2-O-β-D-digalactopyranose (29)Acremonium sp. (BCC 14080) Palm leafKhao Yai National Park, Nakhon Ratchasima Province, Thailand[41]
Arenicolin A (30)Penicillium arenicola (NRRL 8095) -Soil, British Columbia, Canada[42]
Penicillium arenicola (3392) -Soil, pine forest sample, near Kiev, Ukraine[42]
Penicillium arenicola (31507) -Mineral soil, under Pinus resinosa, Ontario, Canada[42]
Penicillium arenicola (31509) -Oil-soaked soil sample, Norman Wells, NW Territories, Canada[42]
Arenicolin B (31)Penicillium arenicola (NRRL 8095) -Soil, British Columbia, Canada[42]
Penicillium arenicola (3392) -Soil, pine forest sample, near Kiev, Ukraine[42]
Penicillium arenicola (31507) -Mineral soil, under Pinus resinosa, Ontario, Canada[42]
Penicillium arenicola (31509) -Oil-soaked soil sample, Norman Wells, NW Territories, Canada.[42]
Aquastatin A (32)Fusarium aquaeductuum (SANK 11089) -Slime fluxes, Karuizawa, Nagano Prefecture, Japan[59]
Cosmospora sp. SF-5060 -Inter-tidal sediment, Gejae Island, Korea[60]
Sporothrix sp. (FN611) -Soil, Jeonju City, Jeollabuk-do, Korea[61]
Depsitinuside (33)Endophytic fungus, internal strain (8984) Leaves of Viburnum tinus -[62]
KS-501 (2-(β-D-galactofuranosyloxy)-6-heptyl-4-hydroxybenzoic acid 3-heptyl-5-hydroxyphenyl ester) (34)Sporothrix sp. (KAC-1985)Fallen leafYamakita-cho, Ashgarakami-gun, Kanagawa Prefecture, Japan[56,63]
KS-502 (2-(β-D-galactofuranosyloxy)6-heptyl-4-hydroxybenzoic acid 4-carboxy-3-heptyl-5-hydroxyphenyl ester) (35)Sporothrix sp. (KAC-1985)Fallen leafYamakita-cho, Ashgarakami-gun, Kanagawa Prefecture, Japan[56,63]
CRM646-A (36)Acremonium sp. (MT70646)-Soil, Geryong, Kongju, Korea[43,44,47]
CRM646-B (37)Acremonium sp. (MT70646) -Soil, Geryong, Kongju, Korea[43,44,47]
Sterenin A (38)Stereum sp. (SANK 21205)-Spore print of fresh basidiocarps, Gunma Prefecture,
Japan		[64]
Sterenin B (39)Stereum sp. (SANK 21205)-Spore print of fresh basidiocarps, Gunma Prefecture,
Japan		[64]
Sterenin C (40)Stereum sp. (SANK 21205)-Spore print of fresh basidiocarps, Gunma Prefecture,
Japan		[64]
Sterenin D (41)Stereum sp. (SANK 21205) -Spore print of fresh basidiocarps, Gunma Prefecture,
Japan		[64]
Sterenin K (42)Stereum hirsutum (EU851110) -Tibetan mountain[53]
Sterenin L (43)Stereum hirsutum (EU851110) -Tibetan mountain[53]
Sterenin M (44)Stereum hirsutum (EU851110) -Tibetan mountain[53]
Colletotric acid A (45)Phoma sp. (SYSU-SK-7) Healthy branch of
Kandelia candel		Shankou Mangrove Nature Reserve, Guangxi Province, China[46]
Colletotrichum gloeosporioidesStem of Artemisia mongolicaHillsides of the Zijin Mountain, suburb of Nanjing, China[65]
Colletotric acid B (46)Phoma sp. (SYSU-SK-7)Healthy branch of Kandelia candelShankou Mangrove Nature Reserve, Guangxi Province, China[46]
PS-990 (47)Acremonium sp. (KY12702)-Soil, Tokyo, Japan[66]
Thielavin A (48)Chaetomium carinthiacum (ATCC 46463)-American Type Culture Collection [62]
Thielavia sp. (UST030930-004) -12-d Biofilms developed at the pier of the Hong Kong University of Science and Technology in Port Shelter, Hong Kong, China[52]
Endophytic fungus MEXU (27905)Healthy leaves of
Hintonia latiflora 		México[67]
Thielavin B (49)Coniochaeta sp. (10F058a) -Soil, Korea[68]
Chaetomium carinthiacum (ATCC 46463) -American Type Culture Collection[62]
Coniochaeta sp. (10F058a) -Soil, Ochang, Korea.[68]
Thielavin B methyl ester (50)Mycosynthetix fungal strain 55526 -Leaf litter, North Carolina Smoky Mountains, United States.[48]
Thielavin C (51)Chaetomium carinthiacum (ATCC 46463) -American Type Culture Collection[62]
Thielavia terricola (SANK 10475) - [69]
Thielavin D (52)Chaetomium carinthiacum (ATCC 46463) -American Type Culture Collection[62]
Thielavin E (53)Thielavia terricola RF-143- [70]
Thielavin F (54)Chaetomium carinthiacum (ATCC 46463) -American Type Culture Collection[62]
Coniochaeta sp. (10F058a) -Soil, Ochang, Korea[68]
Thielavin G (55)Chaetomium carinthiacum (ATCC 46463) -American Type Culture Collection[62]
Thielavin H (56)Chaetomium carinthiacum (ATCC 46463) -American Type Culture Collection[62]
Thielavia sp UST030930-004 -12-d Biofilms developed at the pier of the Hong Kong University of Science and Technology in Port Shelter, Hong Kong, China[52]
Thielavin I (57)Chaetomium carinthiacum (ATCC 46463) -American Type Culture Collection[62]
Thielavin J (58)Chaetomium carinthiacum (ATCC 46463) -American Type Culture Collection[62]
Thielavia sp UST030930-004 -12-d Biofilms developed at the pier of the Hong Kong University of Science and Technology in Port Shelter, Hong Kong, China[52]
Endophytic fungus MEXU 27905 Healthy leaves of
Hintonia latiflora 		México[67]
Thielavin K (59)Chaetomium carinthiacum (ATCC 46463) -American Type Culture Collection[62]
Thielavia sp UST030930-004 -12-d Biofilms developed at the pier of the Hong Kong University of Science and Technology in Port Shelter, Hong Kong, China[52]
Endophytic fungus MEXU 27905 Healthy leaves of
Hintonia latiflora 		México[67]
Thielavin L (60)Chaetomium carinthiacum (ATCC 46463) -American Type Culture Collection[62]
Thielavin M (61)Chaetomium carinthiacum (ATCC 46463) -American Type Culture Collection[62]
Thielavin N (62)Chaetomium carinthiacum (ATCC 46463) -American Type Culture Collection[62]
Thielavin O (63)Chaetomium carinthiacum (ATCC 46463) -American Type Culture Collection[62]
Thielavin P (64)Chaetomium carinthiacum (ATCC 46463) -American Type Culture Collection[62]
Thielavin Q (65)Coniochaeta sp. (10F058a) -Soil, Ochang, Korea[68]
Thielavin S (66)The endophyte Setophoma sp. (KM288713) Fruits of Psidium guajavaSӓo Carlos local trade, São Paulo state, Brazil[19]
Thielavin T (67)The endophyte Setophoma sp. (KM288713) Fruits of Psidium guajavaSӓo Carlos local trade, São Paulo state, Brazil[19]
Thielavin U (68)The endophyte Setophoma sp. (KM288713) Fruits of Psidium guajavaSӓo Carlos local trade, São Paulo state, Brazil[19]
Thielavin V (69)The endophyte Setophoma sp. (KM288713) Fruits of Psidium guajavaSӓo Carlos local trade, São Paulo state, Brazil[19]
Thielavin W (70Thielavia sp UST030930-004 -12-d Biofilms developed at the pier of the Hong Kong University of Science and Technology in Port Shelter, Hong Kong, China[52]
Thielavin X (71)Thielavia sp UST030930-004 -12-d Biofilms developed at the pier of the Hong Kong University of Science and Technology in Port Shelter, Hong Kong, China[52]
Thielavin Y (72)Thielavia sp (UST030930-004) -12-d Biofilms developed at the pier of the Hong Kong University of Science and Technology in Port Shelter, Hong Kong, China[52]
Thielavin Z (73)Thielavia sp (UST030930-004) -12-d Biofilms developed at the pier of the Hong Kong University of Science and Technology in Port Shelter, Hong Kong, China[52]
Thielavin Z1 (74)Thielavia sp (UST030930-004) -12-d Biofilms developed at the pier of the Hong Kong University of Science and Technology in Port Shelter, Hong Kong, China[52]
Thielavin Z2 (75)Thielavia sp (UST030930-004) -12-d Biofilms developed at the pier of the Hong Kong University of Science and Technology in Port Shelter, Hong Kong, China[52]
Thielavin Z3 (76)Thielavia sp (UST030930-004) -12-d Biofilms developed at the pier of the Hong Kong University of Science and Technology in Port Shelter, Hong Kong, China[52]
Thielavin Z4 (77)Thielavia sp (UST030930-004) -12-d Biofilms developed at the pier of the Hong Kong University of Science and Technology in Port Shelter, Hong Kong, China[52]
Thielavin Z5 (78)Thielavia sp (UST030930-004) -12-d Biofilms developed at the pier of the Hong Kong University of Science and Technology in Port Shelter, Hong Kong, China[52]
Thielavin Z6 (79)Thielavia sp. (UST030930-004) -12-d Biofilms developed at the pier of the Hong Kong University of Science and Technology in Port Shelter, Hong Kong, China[52]
Hydroxy-2,5-dimethylphenyl 4-[(2,4-dihydroxy-3,6-dimethylbenzoyl)oxy]-2-hydroxy-3,6-dimethylbenzoate (80)Cladosporium uredinicolaFruits of Psidium guajavaSӓo Carlos local trade, São Paulo state, Brazil[49]
Hydroxy-2,4,5-trimethylphenyl 4-[(2,4-dihydroxy-3,6-dimethylbenzoyl)oxy]-2-hydroxy-3,6-dimethylbenzoate (81)Cladosporium uredinicolaFruits of Psidium guajavaSӓo Carlos local trade, São Paulo state, Brazil[49]
Gyrophoric acid (82)Humicola sp. FO-2942-Soil, Nagasaki, Japan[71,72]
Trivaric acid (83)Fungal strain -Soil, Yunnan Province, China[25]
Cytonic acid A (84)Cytonaema sp. (F32027) Quercus sp.United Kingdom[73]
Cytonic acid B (85)Cytonaema sp. (F32027) Quercus sp.United Kingdom[73]
Amidepsine D (86)Humicola sp. (FO-2942)-Soil, Nagasaki, Japan[74,75]
Amidepsine K (87)Humicola sp. (FO-2942)-Soil, Nagasaki, Japan[71]
Amidepsine A (88)Humicola sp. (FO-2942)-Soil, Nagasaki, Japan[74,75]
Amidepsine B (89)Humicola sp. (FO-2942)-Soil, Nagasaki, Japan[74,75]
Amidepsine C (90)Humicola sp. (FO-2942)-Soil, Nagasaki, Japan[74,75]
Amidepsine E (91)Humicola sp. (FO-5969)-Soil, Asaka, Saitama, Japan[76]
Amidepsine F (92)Humicola sp. (FO-2942)-Soil, Nagasaki, Japan[71]
Amidepsine G (93)Humicola sp. (FO-2942)-Soil, Nagasaki, Japan[71]
Amidepsine H (94)Humicola sp. (FO-2942)-Soil, Nagasaki, Japan[71]
Amidepsine I (95)Humicola sp. (FO-2942)-Soil, Nagasaki, Japan[71]
Amidepsine J (96)Humicola sp. (FO-2942)-Soil, Nagasaki, Japan[71]
44-CJ-21,164 (97)Chloridium sp. (CL48903).-China[77]
Thielocin A1α (98)Thielavia terricola (RF-143)-Culture[78]
Thielocin A1β (99)Thielavia terricola (RF-143)-Culture[78]
Thielocin A2α (100)Thielavia terricola (RF-143)-Culture[70]
Thielocin A2β (101)Thielavia terricola (RF-143)-Culture[70]
Thielocin A4α (102)Thielavia terricola (RF-143)-Culture[79]
Thielocin A4β (103)Thielavia terricola (RF-143)-Culture[79]
Thielocin A3 (104)Thielavia terricola (RF-143)-Culture[70]
Thielocin B1 (105)Thielavia terricola (RF-143)-Culture[70]
Thielocin B2 (106)Thielavia terricola (RF-143)-Culture[70]
Thielocin B3 (107)Thielavia terricola (RF-143)-Culture[80]
Thielocin B3 monomethyl ester B (108)Thielavia terricola (RF-143)-Culture[80]
Thielocin B3 monomethyl ester C (109)Thielavia terricola (RF-143)-Culture[80]
Thielocin B3 monomethyl ester D (110)Thielavia terricola (RF-143)-Culture[80]
Table
Table 2. Biological activities of fungal depsides.
Table 2. Biological activities of fungal depsides.
Compound NameActivityAssay/Microorganism/Model/EnzymeResultsPositive ControlRef.
Lecanoric acid (1)AntitumorColorimetric CTC/HepG240.0 µM (IC50)T-2 toxin 10.0 µM (IC50)[37]
Ethyl lecanorate (2)AntitumorColorimetric CTC/HepG240.0 µM (IC50)T-2 toxin 10.0 µM (IC50)[37]
AntitumorColorimetric CTC/CCF-STTG154.0 µM (IC50)T-2 toxin 10.0 µM (IC50)[37]
Aspergiside A (3)AntibacterialAgar diffusion assay/S. aureus ATCC259238 µg/mL (MIC)Vancomycin 0.25 µg/mL (MIC)[38]
AntibacterialAgar diffusion assay/MRSA8 µg/mL (MIC)Vancomycin 0.50 µg/mL (MIC)[38]
AntifungalAgar diffusion assay/C. albicans NCPF3153200 µg/mL (MIC)Amphotericin B 0.25 µg/mL (MIC)[38]
AntibacterialAgar diffusion assay/C. neoformans ATCC 901364 µg/mL (MIC)Amphotericin B 0.25 µg/mL (MIC)[38]
AntifungalAgar diffusion assay/M. gypseum SH-MU-4128 µg/mL (MIC)Miconazole 1.0 µg/mL (MIC)[38]
AntitumorMTT/KB53.69 µM (IC50)Ellipticine 10.56 µM (IC50)
Doxorubicin 0.65 µM (IC50)		[38]
AntitumorMTT/MCF-754.42 µM (IC50)Doxorubicin 16.83 µM (IC50)
Tamoxifen 20.78 µM (IC50)		[38]
AntitumorMTT/Vero83.75 µM (IC50)Ellipticine 4.55 µM (IC50)[38]
Aspergiside B (4)AntibacterialAgar diffusion assay/S. aureus ATCC25923128 µg/mL (MIC)Vancomycin 0.25 µg/mL (MIC)[38]
AntibacterialAgar diffusion assay/MRSA128 µg/mL (MIC)Vancomycin 0.50 µg/mL (MIC)[38]
AntibacterialAgar diffusion assay/C. neoformans ATCC 901332 µg/mL (MIC)Amphotericin B 0.25 µg/mL (MIC)[38]
AntitumorMTT/Vero cells114.40 µM (IC50)Ellipticine 4.55 µM (IC50)[38]
Aspergiside C (5)AntibacterialAgar diffusion assay/S. aureus ATCC25923200 µg/mL (MIC)Vancomycin 0.25 µg/mL (MIC)[38]
AntibacterialAgar diffusion assay/MRSA200 µg/mL (MIC)Vancomycin 0.50 µg/mL (MIC)[38]
AntibacterialAgar diffusion assay/C. neoformans ATCC 9013200 µg/mL (MIC)Amphotericin B 0.25 µg/mL (MIC)[38]
AntitumorMTT/Vero cells45.07 µM (IC50)Ellipticine 4.55 µM (IC50)[38]
3-Hydroxy-2,5-dimethylphenyl 2,4-dihydroxy-3,6-dimethylbenzoate (9)AntibacterialMicrobroth dilution/S. aureus250 µg/mL (MIC)Vancomycin and
tetracycline		[49]
AntibacterialMicrobroth dilution/B. subtilis25 µg/mL (MIC)Vancomycin and
tetracycline		[49]
AntibacterialMicrobroth dilution/P. aeruginosa25 µg/mL (MIC)Vancomycin and
tetracycline		[49]
Colletotric acid C (11)AntibacterialAgar diffusion assay/B. subtilis9.70 µg/mL (MIC)Ampicillin 0.07 µg/mL (MIC)[46]
Agonodepside A (12)Enoyl-ACP reductase inhibitionFluorometric InhA assay/M. tuberculosis InhA74 µM (IC50)Triclosan 3 µM (IC50)[50]
Thielavin Z7 (15)Antifouling Balanus Amphitrite(cyprid larvae)3.20 µM (EC50)Butenolide 4.62 µM (EC50)[52]
Sterenin J (16)α-Glucosidase inhibitoryColorimetric/α-Glucosidase 65.70 µM (IC50)Acarbose 640.88 µM (IC50)[53]
Sterenin E (17)α-Glucosidase inhibitoryColorimetric/α-Glucosidase 7.62 µM (IC50)Acarbose 640.88 µM (IC50)[53]
Sterenin F (18)α-Glucosidase inhibitoryColorimetric/α-Glucosidase 3.06 µM (IC50)Acarbose 640.88 µM (IC50)[53]
Sterenin G (19)α-Glucosidase inhibitoryColorimetric/α-Glucosidase 6.03 µM (IC50)Acarbose 640.88 µM (IC50)[53]
Sterenin H (20)α-Glucosidase inhibitoryColorimetric/α-Glucosidase 22.70 µM (IC50)Acarbose 640.88 µM (IC50)[53]
Sterenin I (21)α-Glucosidase inhibitoryColorimetric/α-Glucosidase 72.50 µM (IC50)Acarbose 640.88 µM (IC50)[53]
MS-3 (22)AntibacterialPlate diffusion/B. cereus25 mm (IZD)Streptomycin 28 mm (IZD)
Penicillin G 28 mm (IZD)		[57]
AntibacterialPlate diffusion/B. subtilis25 mm (IZD)Streptomycin 32 mm (IZD)
Penicillin G 28 mm (IZD)		[57]
AntibacterialPlate diffusion/S. aureus28 mm (IZD)Streptomycin 30 mm (IZD)
Penicillin G 27 mm (IZD)		[57]
α-Glucosidase inhibitoryColorimetric/α-Glucosidase inhibitor23.82 µM (IC50)Acarbose 640.88 µM (IC50)[53]
4′-Hydroxy-5′-methoxy-6′-(3″-methyl-2″-butenyl)-phenyl-2,4-dihydroxy-6-methyl-benzoate/
4-Hydroxy-3-methoxy-2-(3-methylbut-2-en-1-yl)phenyl 2,4-dihydroxy-6-methylbenzoate (23)		Anti-inflammatory
NO inhibitory potential		LPS-induced macrophages RAW 264.7 19.17 µM (IC50)Hydrocortisone 48.15 µM (IC50)[40]
Antibacterial Agar plate diffusion/MRSA25 µg/mL (MIC)Ancomycin 1.0 µg/mL (MIC) [40]
Antibacterial Agar plate diffusion/S. aureus25 µg/mL (MIC)Ancomycin 1.0 µg/mL (MIC)[40]
Antibacterial Agar plate diffusion/B. subtilis25 µg/mL (MIC)Ancomycin 0.5 µg/mL (MIC)[40]
AntitumorMTT/A54913.14 µM (IC50)Cisplatin 14.33 µM (IC50)[40]
AntitumorMTT/HepG249.02 µM (IC50)Cisplatin 18.74 µM (IC50)[40]
α-Glucosidase inhibitoryColorimetric/α-Glucosidase inhibitor14.17 µM (IC50)Acarbose 640.88 µM (IC50)[53]
4′-Hydroxy-6′-(3″-methyl-2″-butenyl)-phenyl-2,4-dihydroxy-6-methyl-benzoate (24)AntibacterialAgar plate diffusion/MRSA25 µg/mL (MIC)Ancomycin 1.0 µg/mL (MIC) [40]
Antibacterial Agar plate diffusion/S. aureus25 µg/mL (MIC)Ancomycin 1.0 µg/mL (MIC)[40]
Antibacterial Agar plate diffusion/B. subtilis50 µg/mL (MIC)Ancomycin 0.5 µg/mL (MIC)[40]
KS-501a (27)Antimalarial activityMicroculture radioisotope technique/Plasmodium falciparum K19.9 µM (IC50)Dihydroartemisinin 0.0039 µM (IC50)[41]
AntitumorMTT/KB13.0 µM (IC50)Ellipticine 1.99 µM (IC50)[41]
AntitumorMTT/BC8.8 µM (IC50)Ellipticine 0.49 µM (IC50)[41]
AntitumorMTT/NC1-H187 13.6 µM (IC50)Ellipticine 1.77 µM (IC50)[41]
AntitumorMTT/Vero cells34.3 µM (IC50)Ellipticine 1.94 µM (IC50)[41]
KS-501a-2-O-β-D-
galactopyranose (28)		AntitumorMTT/KB>25 µM (IC50)Ellipticine 1.99 µM (IC50)[41]
AntitumorMTT/BC4.4 µM (IC50)Ellipticine 0.49 µM (IC50)[41]
AntitumorMTT/NC1-H187 13.9 µM (IC50)Ellipticine 1.77 µM (IC50)[41]
KS-501a-2-O-β-D-
digalactopyranose (29)		AntitumorMTT/KB>25 µM (IC50)Ellipticine 1.99 µM (IC50)[41]
AntitumorMTT/BC20.2 µM (IC50)Ellipticine 0.49 µM (IC50)[41]
AntitumorMTT/NC1-H187 >25 µM (IC50)Ellipticine 1.77 µM (IC50)[41]
AntitumorMTT/Vero cells32.1 µM (IC50)Ellipticine 1.94 µM (IC50)[41]
Arenicolin A (30)AntitumorImmunocytochemistry ICC/HCT-1167.3 µM (IC50)5-FU 6.5 µM (IC50)[42]
AntitumorImmunocytochemistry ICC/IMR-326.0 µM (IC50)5-FU 5.7 µM (IC50)[42]
AntitumorImmunocytochemistry ICC/BT-4749.7 µM (IC50)-[42]
Sterenin A (38)11β-HSD inhibitory Luminescence immunoassay/HTRF cortisol 240 nM (IC50)-[64]
α-Glucosidase inhibitoryColorimetric/α-Glucosidase 25.10 µM (IC50)Acarbose 640.88 µM (IC50)[53]
Sterenin B (39)11β-HSD inhibitory Luminescence immunoassay/HTRF cortisol6600 nM (IC50)-[64]
α-Glucosidase inhibitoryColorimetric/α-Glucosidase inhibitor12.23 µM (IC50)Acarbose 640.88 µM (IC50)[53]
Sterenin C (40)11β-HSD inhibitory Luminescence immunoassay/HTRF cortisol230 nM (IC50)-[64]
α-Glucosidase inhibitoryColorimetric/α-Glucosidase inhibitor3.31 µM (IC50)Acarbose 640.88 µM (IC50)[53]
Sterenin D (41)11β-HSD inhibitory Luminescence immunoassay/HTRF cortisol2600 nM (IC50)-[64]
AntifungalPlate diffusion/B. cinerea50 µg/mL (MFC)Rovral 10 µg/mL (MFC)[58]
AntifungalPlate diffusion/B. cinerea10 µg/mL (MIC)Rovral 1 µg/mL (MFC)[58]
Sterenin K (42)α-Glucosidase inhibitoryColorimetric/α-Glucosidase 36.64 µM (IC50)Acarbose 640.88 µM (IC50)[53]
Sterenin L (43)α-Glucosidase inhibitoryColorimetric/α-Glucosidase 13.09 µM (IC50)Acarbose 640.88 µM (IC50)[53]
Sterenin M (44)α-Glucosidase inhibitoryColorimetric/α-Glucosidase 27.52 µM (IC50)Acarbose 640.88 µM (IC50)[53]
Colletotric acid A (45)AntibacterialAgar diffusion assay/B. subtilis25 µg/mL (MIC)Ampicillin 0.05 µg/mL (MIC)[65]
AntibacterialAgar diffusion assay/B. subtilis6.55 µg/mL (MIC)Ampicillin 0.07 µg/mL (MIC)[46]
AntibacterialAgar diffusion assay/S. aureus50 µg/mL (MIC)Ampicillin 0.5 µg/mL (MIC)[65]
AntibacterialAgar diffusion assay/S. lutea50 µg/mL (MIC)Ampicillin 0.01 µg/mL (MIC)[65]
AntibacterialAgar diffusion assay/H. lutea50 µg/mL (MIC)Triadimefon 20 µg/mL (MIC)[65]
AntibacterialAgar diffusion assay/P. aeruginosa3.27 µg/mL (MIC)Ampicillin 0.15 µg/mL (MIC)[46]
AntibacterialAgar diffusion assay/MRSA6.28 µg/mL (MIC)Ampicillin 0.15 µg/mL (MIC)[46]
AntibacterialAgar diffusion assay/S. typhimurium26.20 µg/mL (MIC)Ampicillin 0.31 µg/mL (MIC)[46]
AntifungalAgar diffusion assay/C. albicans3.27 µg/mL (MIC)Ketoconazole 0.10 µg/mL (MIC)[46]
AntitumorMTT/MDA-MB-43537.01 µM (IC50)Epirubicin 0.26 µM (IC50)[46]
AntitumorMTT/A54937.73 µM (IC50)Epirubicin 5.60 µM (IC50)[46]
Colletotric acid B (46)AntibacterialAgar diffusion assay/P. aeruginosa1.67 µg/mL (MIC)Ampicillin 0.15 µg/mL (MIC)[46]
AntibacterialAgar diffusion assay/MRSA3.36 µg/mL (MIC)Ampicillin 0.15 µg/mL (MIC)[46]
AntitumorMTT/MDA-MB-43516.82 µM (IC50)Epirubicin 0.26 µM (IC50)[46]
AntitumorMTT/A54920.75 µM (IC50)Epirubicin 5.60 µM (IC50)[46]
AntibacterialAgar diffusion assay/B. subtilis26.90 µg/mL (MIC)Ampicillin 0.07 µg/mL (MIC)[46]
Thielavin A (48)Phospholipase A (PLA) inhibitionRat PLA2-II43 µM (IC50)Mepacrine 320 µM (IC50)
p-Bromophenacyl bromide 6.7 µM (IC50)
Manoalide 2.0 µM (IC50)		[70]
Human PLA2-II29 µM (IC50)Mepacrine 76 µM (IC50)
p-Bromophenacyl bromide 34 µM (IC50)
Manoalide 1.5 µM (IC50)
Antifouling Balanus amphitrite (cyprid larvae)54.99 µM (EC50)Butenolide 4.62 µM (EC50)[52]
Anti-diabeticColorimetric/α-Glucosidase inhibitor (αGHY)23.8 µM (IC50)Acarbose 545 µM (IC50[67]
Prostaglandin synthesis inhibitionConversion of AA into PGH210 µM (IC50)Indomethacin 30 µM (IC50)[69,81]
Conversion of PGH2 into PGE240 µM (IC50)Indomethacin 130 µM (IC50)
Conversion of PGE2 into TXA2150 µM (IC50)Imidazole 200 µM (IC50)
Thielavin B (49)Phospolipase A (PLA) inhibitionRat PLA2-II1.3 µM (IC50)Mepacrine 320 µM (IC50)
p-Bromophenacyl bromide 6.7 µM (IC50)
Manoalide 2.0 µM (IC50)		[70]
Human PLA2-II2.4 µM (IC50)Mepacrine 76 µM (IC50)
p-Bromophenacyl bromide 34 µM (IC50)
Manoalide 1.5 µM (IC50)
Prostaglandin synthesis inhibition Conversion of AA into PGH240 µM (IC50)Indomethacin 30 µM (IC50)[69,81]
Conversion of PGH2 into PGE29 µM (IC50)Indomethacin 130 µM (IC50)
Conversion of PGE2 into TXA2350 µM (IC50)Imidazole 200 µM (IC50)
Thielavin B methyl ester (50)AntitumorSRB/MCF-77.3 µM (IC50)0.07 µM (IC50)[48]
AntitumorSRB/H4606.6 µM (IC50)< 0.01 µM (IC50)[48]
AntitumorSRB/SF2688.1 µM (IC50)0.04 µM (IC50)[48]
Thielavin C (51)PLA inhibitionRat PLA2-II0.46 µM (IC50)Mepacrine 320 µM (IC50)
p-Bromophenacyl bromide 6.7 µM (IC50)
Manoalide 2.0 µM (IC50)		[70]
Human PLA2-II2.1 µM (IC50)Mepacrine 76 µM (IC50)
p-Bromophenacyl bromide 34 µM (IC50)
Manoalide 1.5 µM (IC50)
Thielavin D (52)PLA inhibitionRat PLA2-II1.1 µM (IC50)Mepacrine 320 µM (IC50)
p-Bromophenacyl bromide 6.7 µM (IC50)
Manoalide 2.0 µM (IC50)		[70]
Human PLA2-II6.2 µM (IC50)Mepacrine 76 µM (IC50)
p-Bromophenacyl bromide 34 µM (IC50)
Manoalide 1.5 µM (IC50)
Thielavin E (53)PLA inhibitionRat PLA2-II4.5 µM (IC50)Mepacrine 320 µM (IC50)
p-Bromophenacyl bromide 6.7 µM (IC50)
Manoalide 2.0 µM (IC50)		[70]
Human PLA2-II9.3 µM (IC50)Mepacrine 76 µM (IC50)
p-Bromophenacyl bromide 34 µM (IC50)
Manoalide 1.5 µM (IC50)
Thielavin H (56)Antifouling Balanus amphitrite12.64 µM (EC50)Butenolide 4.62 µM (EC50)[52]
Thielavin J (58)Anti-diabeticColorimetric/α-Glucosidase inhibitor (αGHY)15.8 µM (IC50)Acarbose 545 µM (IC50)[67]
Thielavin K (59)Anti-diabeticColorimetric/α-Glucosidase inhibitor (αGHY)22.1 µM (IC50)Acarbose 545 µM (IC50)[67]
Thielavin S (66)AntibacterialMicrobroth dilution/S. aureus ATCC 25923100 µg/mL (MIC)Tetracycline 3.12 µg/mL (MIC)[19]
Thielavin T (67)AntimicrobialMicrobroth dilution assay/S. aureus ATCC 259236.25 µg/mL (MIC)Tetracycline 3.12 µg/mL (MIC) [19]
Thielavin U (68)AntibacterialMicrobroth dilution assay/S. aureus ATCC 2592350 µg/mL (MIC)Tetracycline 3.12 µg/mL (MIC)[19]
Thielavin V (69)AntibacterialMicrobroth dilution assay/S. aureus ATCC 2592325 µg/mL (MIC)Tetracycline 3.12 µg/mL (MIC)[19]
Thielavin W (70)Antifouling Balanus Amphitrite(cyprid larvae)2.95 µM (EC50)Butenolide 4.62 µM (EC50)[52]
Thielavin X (71)Antifouling Balanus Amphitrite(cyprid larvae)3.13 µM (EC50)Butenolide 4.62 µM (EC50)[52]
Thielavin Y (72)Antifouling Balanus Amphitrite(cyprid larvae)5.78 µM (EC50)Butenolide 4.62 µM (EC50)[52]
Thielavin Z2 (75)Antifouling Balanus Amphitrite(cyprid larvae)69.19 µM (EC50)Butenolide 4.62 µM (EC50)[52]
Thielavin Z3 (76)Antifouling Balanus Amphitrite
(cyprid larvae)		4.23 µM (EC50)Butenolide 4.62 µM (EC50)[52]
Thielavin Z4 (77)Antifouling Balanus Amphitrite(cyprid larvae)50.50 µM (EC50)Butenolide 4.62 µM (EC50)[52]
Thielavin Z5 (78)Antifouling Balanus Amphitrite(cyprid larvae)25.86 µM (EC50)Butenolide 4.62 µM (EC50)[52]
Thielavin Z6 (79)Antifouling Balanus Amphitrite(cyprid larvae)17.86 µM (EC50)Butenolide 4.62 µM (EC50)[52]
3-Hydroxy-2,5-dimethylphenyl 4-[(2,4-dihydroxy-3,6-dimethylbenzoyl)oxy]-2-hydroxy-3,6-
dimethylbenzoate (80)		AntibacterialMicrobroth dilution/S. aureus250 µg/mL (MIC)Vancomycin and
tetracycline		[49]
AntibacterialMicrobroth dilution/B. subtilis250 µg/mL (MIC)Vancomycin and
tetracycline		[49]
AntibacterialMicrobroth dilution/P. aeruginosa250 µg/mL (MIC)Vancomycin and
tetracycline		[49]
AntibacterialMicrobroth dilution/E. coli250 µg/mL (MIC)Vancomycin and
tetracycline		[49]
3-Hydroxy-2,4,5-trimethylphenyl 4-[(2,4-dihydroxy-3,6-dimethylbenzoyl)oxy]-2-hydroxy-3,6-
dimethylbenzoate (81)		AntibacterialMicrobroth dilution/S. aureus250 µg/mL (MIC)Vancomycin and
tetracycline		[49]
AntibacterialMicrobroth dilution/B. subtilis25 µg/mL (MIC)Vancomycin and
tetracycline		[49]
AntibacterialMicrobroth dilution/P. aeruginosa25 µg/mL (MIC)Vancomycin and
tetracycline		[49]
AntibacterialMicrobroth dilution/E. coli250 µg/mL (MIC)Vancomycin and
tetracycline		[49]
Amidepsine D (86)DGAT1 inhibitionRat liver microsomes17.5 µM (IC50)-[74]
DGAT2 inhibitionRat liver microsomes30 µM (IC50) [71,82]
Triacylglycerol inhibitionRaji cells2.82 µM (IC50)-[74]
AntibacterialDisk diffusion/B. subtilis ATCC66338.0 mm (IZD)-[74]
Amidepsine A (88)DGAT1 inhibitionRat liver microsomes10.2 µM (IC50)-[74]
DGAT2 inhibitionRat liver microsomes70 µM (IC50)-[71,82]
Triacylglycerol inhibitionRaji cells15.5 µM (IC50)-[74]
AntibacterialDisk diffusion/B. subtilis ATCC663311.0 mm (IZD)-[74]
Amidepsine B (89)DGAT1 inhibitionRat liver microsomes19.2 µM (IC50)-[74]
DGAT2 inhibitionRat liver microsomes60 µM (IC50)-[71,82]
Triacylglycerol inhibitionRaji cells3.35 µM (IC50)-[74]
AntibacterialDisk diffusion/B. subtilis ATCC66337.0 mm (IZD)-[74]
Amidepsine C (90)DGAT1 inhibitionRat liver microsomes51.6 µM (IC50)-[74]
DGAT2 inhibitionRat liver microsomes100 µM (IC50)-[71,82]
Triacylglycerol inhibitionRaji cells17.2 µM (IC50)-[74]
AntibacterialDisk diffusion/B. subtilis ATCC66339.0 mm (IZD)-[74]
Amidepsine E (91)Triacylglycerol inhibitionRaji cells91 µM (IC50)-[76]
DGAT1 inhibitionRat liver microsomes124 µM (IC50)-[76]
Amidepsine J (96)DGAT1 inhibitionRat liver microsomes40 µM (IC50)-[71]
DGAT2 inhibitionRat liver microsomes40 µM (IC50) [71]
CJ-21,164 (97)G6Pase inhibition Colorimetric assay102% (% inhibition) [77]
Glucose output inhibition Colorimetric assay81% (% inhibition)-[77]
Thielocin A1i (99)PLA inhibitionHuman PLA2-II6.2 µM (IC50)-[78,80,83,84]
Human PLA2-I140 µM (IC50)-
Ki value human PLA2-II12 µM-
Rat PLA2-II0.0033 µM (IC50)Mepacrine 240 µM (IC50)
Vipera russelli venom PLA2-II 17 µM (IC50)
Crotalus adamanteus venom PLA2-II17 µM (IC50)
Porcine pancreas PLA2-I 63 µM (IC50)
Rat PLA2-I21 µM (IC50)Mepacrine 135 µM (IC50)
Bee venom PLA2-I2 µM (IC50)
Naja naja venom PLA2-I 7.1 µM (IC50)
N. mocambique venom PLA2-I9.3 µM (IC50)
Bee venom PLA21.4 µM (IC50)p-Bromophenacyl bromide 80 µM (IC50)[83,84]
Bee venom PLA2-induced paw edema42.4 (mg)
Ki value Bee venom PLA20.57 µM
Thielocin A2α (100)PLA inhibitionRat PLA2-II0.051 µM (IC50)Mepacrine 320 µM (IC50)
p-Bromophenacyl bromide 6.7 µM (IC50)
Manoalide 2.0 µM (IC50)		[70]
Human PLA2-II0.31 µM (IC50)Mepacrine 76 µM (IC50)
p-Bromophenacyl bromide 34 µM (IC50)
Manoalide 1.5 µM (IC50)
Thielocin A2β (101)PLA inhibitionRat PLA2-II0.038 µM (IC50)Mepacrine 320 µM (IC50)
p-Bromophenacyl bromide 6.7 µM (IC50)
Manoalide 2.0 µM (IC50)		[70]
Human PLA2-II 0.24 µM (IC50)Mepacrine 76 µM (IC50)
p-Bromophenacyl bromide 34 µM (IC50)
Manoalide 1.5 µM (IC50)		[70]
Rat PLA2-II0.032 µM (IC50)Mepacrine 320 µM (IC50)
p-Bromophenacyl bromide 6.7 µM (IC50)
Manoalide 2.0 µM (IC50)		[70]
Human PLA2-II0.39 µM (IC50)Mepacrine 76 µM (IC50)
p-Bromophenacyl bromide 34 µM (IC50)
Manoalide 1.5 µM (IC50)
Thielocin B1 (105)PLA inhibitionRat PLA2-II0.0078 µM (IC50)Mepacrine 320 µM (IC50)
p-Bromophenacyl bromide 6.7 µM (IC50)
Manoalide 2.0 µM (IC50)		[70]
Human PLA2-II0.17 µM (IC50)Mepacrine 76 µM (IC50)
p-Bromophenacyl bromide 34 µM (IC50)
Manoalide 1.5 µM (IC50)
Thielocin B2 (106)PLA inhibitionRat PLA2-II0.070 µM (IC50)Mepacrine 320 µM (IC50)
p-Bromophenacyl bromide 6.7 µM (IC50)
Manoalide 2.0 µM (IC50)		[70]
Human PLA2-II2.7 µM (IC50)Mepacrine 76 µM (IC50)
p-Bromophenacyl bromide 34 µM (IC50)
Manoalide 1.5 µM (IC50)
Thielocin B3 (107)PLA inhibitionHuman PLA2-I18 µM (IC50)-[70,80]
Rat PLA2-II0.012 µM (IC50)Mepacrine 320 µM (IC50)
p-Bromophenacyl bromide 6.7 µM (IC50)
Manoalide 2.0 µM (IC50)
Human PLA2-II0.076 µM (IC50)Mepacrine 76 µM (IC50)
p-Bromophenacyl bromide 34 µM (IC50)
Manoalide 1.5 µM (IC50)
Rat PLA2-I2.8 µM (IC50)-
Mean Ki0.98 µM-
Snake venom PLA20.0045 µM (IC50)
1.6 µM (ED50)		-
Exudate volume after carrageenan 1.60 mL (conc. 1 mg/kg)
1.15 mL (conc. 3 mg/kg)		Indomethacin 1.08 mL (conc. 1 mg/kg)
Dexamethasone
0.60 mL (conc. 0.1 mg/kg)
PLA2 activityin pleural exudate after carrageenan2.22 pmol/minute/mL (conc. 1 mg/kg)
0.76 pmol/minute/mL (conc. 3 mg/kg)		Indomethacin 7.36 pmol/minute/mL (conc. 1 mg/kg)
Dexamethasone
7.94 pmol/minute/mL (conc. 0.1 mg/kg)
Thielocin B3 monomethyl
ester B (108)		PLA inhibitionHuman PLA2-II0.20 µM (IC50)-[80]
Snake venom PLA20.032 µM (IC50)
5.2 µM (ED50)		-
Thielocin B3 monomethyl
ester C (109)		PLA inhibitionHuman PLA2-II0.28 µM (IC50)-[80]
Snake venom PLA20.31 µM (IC50)
5.2 µM (ED50)		-
Thielocin B3 monomethyl
ester D (110)		PLA inhibitionHuman PLA2-II51 µM (IC50)-[80]
Snake venom PLA2>100 µM (IC50)
7.6 µM (ED50)		-
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Ibrahim, S.R.M.; Sirwi, A.; Eid, B.G.; Mohamed, S.G.A.; Mohamed, G.A. Fungal Depsides—Naturally Inspiring Molecules: Biosynthesis, Structural Characterization, and Biological Activities. Metabolites 2021, 11, 683. https://doi.org/10.3390/metabo11100683

AMA Style

Ibrahim SRM, Sirwi A, Eid BG, Mohamed SGA, Mohamed GA. Fungal Depsides—Naturally Inspiring Molecules: Biosynthesis, Structural Characterization, and Biological Activities. Metabolites. 2021; 11(10):683. https://doi.org/10.3390/metabo11100683

Chicago/Turabian Style

Ibrahim, Sabrin R. M., Alaa Sirwi, Basma G. Eid, Shaimaa G. A. Mohamed, and Gamal A. Mohamed. 2021. "Fungal Depsides—Naturally Inspiring Molecules: Biosynthesis, Structural Characterization, and Biological Activities" Metabolites 11, no. 10: 683. https://doi.org/10.3390/metabo11100683

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop